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ABSTRACT 
FRUCTOSE-1,6-BISPHOSPHATASE 2 INHIBITS SARCOMA PROGRESSION BY 
RESTRAINING MITOCHONDRIAL BIOGENESIS 
Yangpeiwei Huang 
M. Celeste Simon 
 
Sarcomas are uncommon but diverse mesenchymal malignancies arising from connective 
tissues, such as muscle, fat and cartilage. Despite rapid advances in molecular understanding of 
individual subtypes and pathway-specific therapies, the remarkable cellular and genetic 
heterogeneity of soft tissue sarcomas (STS) limits clinical benefit of targeted treatments. A variety 
of metabolism-associated oncogenic signaling pathways have been identified in sarcomas. Both 
these internal and external alterations converge to change cell metabolism, rendering sarcoma 
cells more susceptible to perturbations within metabolic networks. However, how abnormal 
metabolism influences sarcoma growth remains understudied. 
I show that expression of the gluconeogenic isozyme fructose-1,6-bisphosphatase 2 (FBP2) is 
silenced in a broad spectrum of STS subtypes, revealing an apparent common metabolic feature 
shared by diverse STS. Enforced FBP2 re-expression inhibits STS cell and tumor growth through 
two distinct mechanisms. First, cytosolic FBP2 antagonizes elevated glycolysis associated with the 
“Warburg effect”, thereby inhibiting sarcoma cell proliferation. Second, nuclear-localized FBP2 
restrains mitochondrial biogenesis and respiration in a catalytic activity-independent manner by 
inhibiting the expression of nuclear respiratory factor (NRF1) and mitochondrial transcription factor 
A (TFAM). Specifically, nuclear FBP2 colocalizes with the c-Myc transcription factor at the TFAM 
locus and represses c-Myc-dependent TFAM expression. This unique dual function of FBP2 
provides a rationale for its selective suppression in STS, identifying a potential metabolic 
vulnerability and possible future therapeutic target.   
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CHAPTER 1 INTRODUCTION 
This chapter has been adapted from the following review article: Huangyang, Peiwei, and M. 
Celeste Simon. "Hidden features: exploring the non-canonical functions of metabolic enzymes." 
Disease models & mechanisms 11.8 (2018): dmm033365. 
https://dmm.biologists.org/content/11/8/dmm033365.abstract 
Introduction to soft tissue sarcomas 
Soft tissue sarcomas (STS) encompass a diverse group of mesenchymal tumors arising from 
connective tissues, such as muscle, fat and cartilage. Each year, approximately 13,000 new cases 
are diagnosed in the United States, and 5,000 patients succumb to this disease (Siegel et al., 2019). 
Collectively, STS are classified into more than 70 subtypes based on pathological and clinical 
features, ranging from indolent to highly invasive and metastatic (Cancer Genome Atlas Research 
Network, 2017; Fletcher, 2014). Liposarcoma, undifferentiated pleomorphic sarcoma (UPS), and 
fibrosarcoma represent 40% of newly diagnosed sarcomas in adults (Lehnhardt et al., 2009). 
Although recent studies have integrated genome-scale analyses of the molecular mechanisms 
underlying sarcomagenesis and progression (Cancer Genome Atlas Research Network, 2017; 
Taylor et al., 2011), these cancers remain understudied due to their extensive heterogeneity. 
Current treatment options are limited to standard surgical resection, radiotherapy and 
chemotherapy (Mehren et al., 2018); however, response rates to cytotoxic chemotherapy are only 
10-25% (Linch et al., 2014). Highly divergent genomic alterations and low response rates to 
traditional treatments necessitate development of effective therapies that exploit common features 
of sarcoma progression.  
Metabolic alterations in soft tissue sarcomas 
Various oncogenic signaling pathways and microenvironmental stresses converge to modify 
cellular metabolism, adapting it to limited nutrient and oxygen availability (Vander Heiden and 
DeBerardinis, 2017). A broad array of oncogenes and tumor suppressors that regulate metabolic 
pathways are mutated in sarcomas, such as PIK3CA (catalytic subunit of phosphatidylinositol 3-
 2 
 
kinase), TP53, and NF1 (Barretina et al., 2010; Cancer Genome Atlas Research Network, 2017). 
In addition to effects imposed by genetic mutations, hypoxic (O2-deprived) tumor 
microenvironments characteristic of STS alter metabolism and are associated with worse prognosis 
(Brizel et al., 1996; Sadri and Zhang, 2013). While reprogrammed metabolic activities likely 
promote sarcoma growth and progression, they also create unique vulnerabilities and therefore 
new opportunities for therapeutic intervention. Previously, labeled isotope infusion of sarcoma 
patients revealed elevated tissue glucose uptake and turnover, accompanied by decreased 
glucose oxidation (Shaw et al., 1988), suggesting abnormal glucose metabolism in these tumors. 
Glycolysis is counterbalanced by anabolic gluconeogenesis to maintain glucose homeostasis, and 
gluconeogenic enzymes play important roles in regulating tumor cell growth and behavior (Wang 
and Dong, 2019).   
Introduction to fructose-1,6-bisphosphatase and its role in cancer 
   Fructose-1,6-bisphosphatase (FBP) is a rate-limiting enzyme that catalyzes the irreversible 
hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate and inorganic phosphate. 
Vertebrates possess two highly conserved FBP isozymes exhibiting 76.6% sequence identity: 
FBP1 is detected primarily in liver and kidney, whereas FBP2 expression is more ubiquitous 
although highest in skeletal muscle and other mesenchymal tissues. Recently, FBP1 loss has been 
found to contribute to the progression of multiple epithelial tumors, including clear cell renal cell 
carcinoma (ccRCC), breast cancer, hepatocellular carcinoma and pancreatic ductal 
adenocarcinoma (Dong et al., 2013; Hirata et al., 2016; Li et al., 2014; Zhu et al., 2015). Several 
mechanisms are implicated in downregulating FBP1, including transcription factor repression (Zhu 
et al., 2015), epigenetic silencing (Bigl et al., 2008; Chen et al., 2011; Yang et al., 2017) and 
proteasome degradation (Jin et al., 2017). 
 
Restoration of FBP1 expression in breast cancer and ccRCC cells strongly antagonizes 
glycolysis through its catalytic activity (Dong et al., 2013; Li et al., 2014); however, FBP1 also 
regulates genes in ccRCC cells through an unanticipated nuclear function. Specifically, we 
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demonstrated that FBP1 directly suppresses the transcriptional activity of hypoxia-inducible factors 
(HIFs) through an enzymatic activity-independent mechanism (Li et al., 2014). HIFs regulate 
several hundred genes, including those encoding the glycolytic enzymes GLUT1, HK2, PFK1 and 
LDHA, to facilitate cellular adaptation to hypoxia (Nakazawa et al., 2016b); thus, FBP1 loss further 
enhances HIF responses. Interestingly, over 90% of ccRCC tumors harbor von Hippel-Lindau (VHL) 
mutations that stabilize HIFs even under normoxia (Nickerson et al., 2008). However, in pVHL-
expressing ccRCC cells, FBP1 no longer inhibits glycolysis and NADPH production, suggesting 
that HIFs are required for FBP1-mediated effects on glucose metabolism. Further investigation 
found that FBP1 physically interacts with both HIF-1a and HIF-2a, and suppresses HIF target gene 
expression by co-localizing with HIF-1a at hypoxia-responsive elements (HREs) within these loci. 
Additionally, the suppression of HIF activity is abolished when a nucleus-excluded FBP1, but not 
the catalytically dead FBP1, is introduced into ccRCC cells (Li et al., 2014). These data suggest 
that FBP1’s activity as a HIF transcriptional co-repressor is restricted to the nucleus in a catalytic-
activity independent manner. 
Whereas FBP1 has been studied in a variety of carcinomas, little is known about the role of 
FBP2 in mesenchymal cells or STS. The consensus nuclear localization sequence between FBP1 
and FBP2 indicates that FBP2 might also preserve some previously unknown nuclear functions, 
which might also be involved in inhibiting sarcoma progression.  
Non-canonical functions of metabolic enzymes 
    With the development of new experimental techniques, advances in cancer metabolism research 
have greatly enhanced our understanding of how cancer cells benefit from altered metabolism to 
support their growth. For example, subcellular fractionation revealed that a majority of key glycolytic 
enzymes are actually present in the nucleus (Kim and Dang, 2005). It is intriguing to speculate that 
these enzymes have unexpected nuclear functions, such as stimulating gene expression, which 
impacts specific cell decisions in response to fuel supply and demand. An emerging paradigm 
proposes that metabolic enzymes, rather than simple components of biochemical pathways, are 
multi-functional proteins. They can act as mediators between growth stimuli, signaling pathways 
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and downstream effectors, over and above the changes in metabolism contributing to many other 
biological functions, such as gene transcription, apoptosis, and cell-cycle progression. 
A key finding from studies of metabolic enzymes is the existence of mechanistic links between 
their nuclear localization and the regulation of transcription. By modulating gene expression, 
metabolic enzymes themselves facilitate adaptation to rapidly changing environments. Furthermore, 
they can directly shape a cell’s epigenetic landscape (Kaelin and McKnight, 2013). Strikingly, 
several metabolic enzymes exert completely distinct functions in different cellular compartments. 
Nuclear fructose bisphosphate aldolase, for example, directly interacts with RNA polymerase III to 
control transcription (Cieśla et al., 2014); whereas in the cytosol, it mediates signal transduction, 
vesicle trafficking and cell motility (Lincet and Icard, 2015). Indeed, a growing list of multifaceted 
enzymes supports the possibility that cells employ existing proteins in different and efficient ways, 
without the need to replicate or transcribe additional genes. We provide an overview of metabolic 
enzymes for which non-canonical functions have been identified (Table 1) and their implications in 
cancer.  
Summary 
The central goal of this study was to characterize the metabolic and transcriptional impacts of 
FBP2 on sarcoma progression. We demonstrate here that FBP2 transcription is markedly silenced 
in the majority of STS subtypes, and that restoring FBP2 expression dramatically inhibits sarcoma 
cell proliferation in vitro and tumor growth in vivo, implicating FBP2 loss as an important general 
event during sarcomagenesis. Isotope tracing and unbiased mass spectrometry analyses of 
liposarcoma, fibrosarcoma and UPS cells demonstrated that glycolysis and TCA cycle activity are 
inhibited by FBP2 restoration. Additionally, RNA-seq analysis indicates that mitochondrial function 
and oxidative phosphorylation (OXPHOS) gene signatures are significantly repressed by FBP2. 
Both FBP1 and FBP2 isozymes share a consensus nuclear localization sequence (NLS) (Gizak et 
al., 2009a; 2009b), and a nucleus-excluded FBP2 mutant has no effect on mitochondrial biogenesis 
and OXPHOS, indicating that nuclear FBP2 regulates mitochondrial function independent of its 
enzymatic activity. Finally, we determined that FBP2 co-localizes with c-Myc at the promoter region 
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of TFAM, which encodes a master regulator of mitochondrial biogenesis, and inhibits c-Myc-
mediated TFAM expression. 
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Table 1. Summary of metabolic enzymes with non-canonical functions. 
Enzymes Canonical 
functions 
Non-canonical functions Refs 
Hexokinase 2 
(HK2) 
Phosphorylate 
glucose to glucose 
6-phosphate 
(G6P) 
Represses the expression of 
genes involved in glucose 
repression  
(Ahuatzi et al., 2004; 
Cheung et al., 2012; Chiara 
et al., 2008; Gottlob et al., 
2001; La Cera et al., 2002; 
Majewski et al., 2004; Neary 
and Pastorino, 2013; 
Pastorino et al., 2002) 
Mitochondrial HK2 protect cells 
from apoptosis by regulating the 
mitochondrial permeability 
transition pore and by limiting the 
production of reactive oxygen 
species 
Phosphogluco
se isomerase 
(PGI) 
Interconvert G6P 
to fructose 6-
phosphate (F6P) 
Acts as an autocrine factor 
extracellularly to elicit cell 
migration and proliferation 
(Ahmad et al., 2011; Fu et 
al., 2011; Funasaka et al., 
2007a; 2007b; Sun et al., 
1999; Watanabe et al., 
1996)  
Phosphofructo
kinase (PFK) 
Phosphorylate 
F6P to fructose 1, 
6-bisphosphate 
(F1, 6BP) 
Nuclear PFK1 binds to 
transcription factor TEAD and 
stabilizes its interaction with 
YAP/TAZ and promotes gene 
expression 
(Enzo et al., 2015) 
6-
phosphofructo
se-2-
kinase/fructose
-2, 6-
bisphosphatas
e 3 (PFKFB3) 
Interconvert F6P 
to fructose 2, 6-
bisphosphate (F2, 
6BP) 
Nuclear PFKFB3 promotes cell-
cycle progression by upregulating 
cell-cycle protein expression and 
downregulating cell-cycle inhibitor 
p27  
(Yalcin et al., 2014; 2009) 
Fructose-1, 6-
bisphosphatas
e 1 (FBP1) 
Hydrolyze F1, 6BP 
to F6P 
Nuclear FBP1 binds to HIFs and 
inhibits its transcriptional 
activation of glycolytic gene 
expression 
(Li et al., 2014)  
Aldolase A Split F1, 6BP to 
dihydroxyacetone 
phosphate (DHAP) 
and 
glyceraldehyde 3-
phosphate (G3P) 
Nuclear aldolase A is involved in 
the cytokinesis through its 
interaction with F-actin and 
Wiskott-Aldrich Syndrome Protein 
(WASP) family proteins 
(Buscaglia et al., 2006; Kao 
et al., 1999; Ritterson Lew 
and Tolan, 2012) 
Glyceraldehyd
e 3-phosphate 
dehydrogenas
e (GAPDH) 
Interconvert G3P 
to 1, 3-
bisphophoglycerat
e (1, 3BPG) 
Binds to colony-stimulating factor-
1 (CSF-1) mRNA and stabilizes 
its transcripts 
(Grosse et al., 1986; Hara et 
al., 2005; Ishitani et al., 
1996; Ishitani and Chuang, 
1996; Sen et al., 2009; 
2008; Sundararaj et al., 
2004; Zheng et al., 2003; 
Zhou et al., 2008) 
GAPDH is a key component in 
OCA-S complex, mediates its 
activation of H2B during S phase 
and promotes cell-cycle 
progression  
Protects telomeres against rapid 
shortening 
Increases DNA synthesis during 
S phase via direct binding to 
ssDNA and stimulating the DNA-
polymerase-a-primase complex 
GAPDH S-nitrosylation promotes 
its nuclear translocation and 
triggers apoptosis 
Mitochondrial GAPDH facilitates 
apoptosis via inducing 
mitochondrial membrane 
permeabilization (MOMP) and 
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subsequent release of 
cytochrome c and AIF 
Phosphoglycer
ate kinase 
(PGK) 
Interconvert 1, 
3BPG to 3-
phosphoglycerate 
(3PG) 
Recognizes primer and robustly 
stimulates DNA synthesis 
catalyzed by DNA polymerase a 
and e 
(Kumble and Vishwanatha, 
1991; Popanda et al., 1998) 
Enolase 1 
(ENO1) 
Interconvert 2-
phosphoglycerate 
to 
phosphoenolpyruv
ate (PEP) 
MYC binding protein-1 (MBP-1) 
transcribes from the same gene 
as ENO1; MBP-1 binds to MYC 
and represses its expression by 
recruiting histone deacetylase 
(HDAC) 
(Feo et al., 2000; Ghosh et 
al., 1999a; 1999b; Hsu et al., 
2008; Wang et al., 2005) 
MBP-1 attenuates Notch1-
mediated c-Myc activation by 
interacting with activated Notch1 
receptor, N1IC 
Pyruvate 
kinase 2 
(PKM2) 
Transfer a 
phosphate group 
from PEP to ADP 
to yield pyruvate 
and ATP 
Acts as a binding partner of Oct-4 
and enhances its transcriptional 
activity 
(Gao et al., 2012; Hosios et 
al., 2015; Jiang et al., 
2014a; 2014b; Lee et al., 
2008; Li et al., 2015; Luo et 
al., 2011; Wang et al., 2014; 
Yang et al., 2012a; 2011; 
2012b) 
Interacts with HIF1a and 
increases p300 recruitment to HIF 
target gene  
Upon EGFR stimulation, PKM2 
binds to b-catenin and co-
activates cyclin D1 and c-Myc 
Kinase activity (controversial): 
PKM2 phosphorylates a variety of 
proteins, such as stat3, Histone 
H3, Bub3 and myosin light chain 
2 (MLC2). PKM2 promotes G1/S 
transition by promoting cyclin D1 
and c-Myc expression and 
chromosome segregation by 
phosphorylating spindle 
checkpoint protein Bub3 
In yeast, Pyk1 (yeast PKM2) 
forms the SESAME complex. 
SESAME interacts with Set1 
methyltransferase and controls 
H3K4me3  
Lactate 
dehydrogenas
e A (LDHA) 
Interconvert 
lactate to pyruvate 
Forms OCA-S complex with 
GAPDH and regulates cell-cycle 
progression 
(Castonguay et al., 2014; 
Popanda et al., 1998; Zheng 
et al., 2003) 
Activates SIRT1 by 
supplementing NAD+ 
Binds to ssDNA and facilitates 
DNA replication by recruiting with 
DNA polymerase a, d, and e 
Aconitase Interconvert citrate 
to isocitrate in the 
TCA cycle 
In yeast, aconitase (Aco1p) is 
essential for mtDNA maintenance 
(Chen et al., 2005) 
Succinyl-CoA 
synthase 
(SCS)  
Interconvert 
sucinyl-CoA to 
succinate in the 
TCA cycle 
SCS-A is associated with mtDNA 
maintenance  
(Phillips et al., 2009) 
Fumarase  Interconvert 
fumarate to malate 
in the TCA cycle 
Participates in DNA damage 
repair in an enzymatic activity 
dependent manner 
(Jiang et al., 2015; Yogev et 
al., 2010) 
Malate 
dehydrogenas
e (MDH) 
Interconvert 
malate to 
Increases p53 stabilization and 
transcriptional activity by 
(Lee et al., 2009; McEwen et 
al., 1963) 
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oxaloacetate in the 
TCA cycle 
facilitating its phosphorylation and 
acetylation 
Pyruvate 
dehydrogenas
e complex 
(PDC) 
Convert pyruvate 
to acetyl-CoA 
Produces acetyl-CoA in the 
nucleus and increases histone 
acetylation 
(Cai et al., 2011; Kim et al., 
2006; Sutendra et al., 2014) 
Promotes cell-cycle progression 
by increasing acetylation of 
histones important for G1/S 
transition and activating S-phase 
regulator expression (P-Rb, E2F, 
cyclin A, and Cdk2) 
ATP-citrate 
lyase (ACLY) 
Convert citrate to 
oxaloacetate and 
acetyl-CoA 
Produces acetyl-CoA and 
increases histone acetylation 
(Lee et al., 2014; Sivanand 
et al., 2017; Wellen et al., 
2009) Upon DNA damage, nuclear 
ACLY promotes homologous 
recombination 
Acetyl-CoA 
synthetase 
short-chain 
family member 
2 (ACSS2) 
Catalyze acetate 
to acetyl-CoA 
Forms a complex with TFEB and 
increases lysosomal and 
autophagy gene expression by 
local histone acetylation 
(Cheng et al., 2015; Li et al., 
2017a; 2017b; Zhao et al., 
2016) 
Provides acetyl-CoA for lysine 
acetyltransferase CREB-binding 
protein (CBP)-mediated HIF-2a 
acetylation 
Methionine 
adenosyltransf
erase IIa 
(MATIIa)  
Produce S-
adenosylmethionin
e (SAM) from 
methionine 
Forms a complex with Maf and 
represses HO-1 expression by 
increasing histone methylation 
and recruiting chromatin 
corepressors 
(Katoh et al., 2011) 
Serine 
hydroxymethylt
ransferase 
(SHMT) 
Interconvert L-
serine to glycine 
and 
tetrahydrofolate to 
5, 10-
methylenetetrahyd
rofolate  
Directs deubiquitinating complex 
BRISC to IFAR1 and protects it 
from lysosomal degradation and 
promotes IFNAR1 signaling  
(Zheng et al., 2013) 
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CHAPTER 2 MATERIALS AND METHODS 
Cell culture 
LPS224, LPS246, T449, T778, T1000, SW872, HT1080, KP250 and 293T cells were tested to 
confirm they are mycoplasma negative, and cultured in DMEM (Life Technologies, 11965-084) 
containing 10% FBS (Gemini, 900-108). C2C12 myoblasts (ATCC, CRL-1772) were propagated in 
DMEM containing 20% FBS. To evaluate differentiation, myoblasts were grown to 80 to 90% 
confluence and switched to 2% horse serum (Life Technologies, 16050-122) in DMEM. For 
metabolic labelling assays, cells were maintained in glucose-free DMEM (Life Technologies, 
11966-025) supplemented with 10% dialyzed FBS (Gemini, 100-108) and 10 mM [1, 2-13C]glucose 
(Sigma-Aldrich, 453188), or supplemented with 10% dialyzed FBS and 2 mM [3-13C]sodium 
pyruvate (Sigma-Aldrich, 490733). Human skeletal muscle myoblasts (HSMM, Lonza, CC-2580) 
were culture in SkBM-2 Basal Medium (Lonza, CC-3246), supplemented with SkGM-2 SingleQuots 
containing GA-1000, human Epidermal Growth Factor, Dexamethasone and L-glutamine (Lonza, 
CC-3244). Differentiation should be initiated when the plated myoblasts reach 80-90% confluence 
and differentiation medium (DMEM with 2% horse serum) was added to the plates and changed 
every 2-3 days. All cells were incubated at 37°C and 5% CO2.  
Mice 
    Xenograft tumor experiments were approved by the Animal Care and Use Committee at the 
University of Pennsylvania. Briefly, ten female NSG mice (the Jackson Laboratory, 6 weeks, 
005557) were injected subcutaneously into both flanks with 2 million LPS246 cells stably 
expressing TetOne-FBP2. Before injection, cells were resuspended in 100 µl PBS mixed with an 
equal volume of Matrigel (Corning, 356234). Once palpable tumors were established, tumor volume 
was measure with a digital caliper. When the average tumor size reached 100 mm3, ten mice were 
randomly separated into two groups: (1) Doxycycline diet (Bio-Serv, S3888) and (2) control diet 
(Bio-Serv, S4207). Upon completion of the experiment, the animals were sacrificed by CO2 
inhalation and xenograft tumors were dissected for downstream analyses. 
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Constructs and Viral Transduction 
    Lentivirus was produced by transfecting 2.5 ×  106 HEK293 cells with the 10 µg indicated 
expression plasmid, 2.5 µg pRSV-Rev, 6.5 µg pMDL, and 3.5 µg pCMV-VSV-G plasmids (4th 
generation lentiviral system) using FuGENE 6 Transfection Kit (Promega, E2691). The virus was 
harvested 48 h after transfection by filtering the virus-containing medium through Amicon Ultra-15 
Centrifugal Filter (Millipore, UFC901024). Virus infection was performed by incubating cells with 
medium containing indicated virus and 8 µg/ml polybrene (Sigma, 107689) for 24 h. Cells were 
allowed to recover in complete medium for 24 h and then selected with puromycin for 48 h. 
Surviving pools were subjected to indicated experiments.  
Sequence verified cDNA constructs were obtained from the Mammalian Gene Collection (GE 
Dharmacon) and were subcloned into the pCDH-CMV-MCS-EF1-Puromycin mammalian 
expression vector (System Biosciences CD510B-1) and pLVX-TetOne-Puro (Clontech, 631847). 
FBP2 cDNA construct: MHS6278-211687897 (Accession, BC117477). The FBP24KA and 
FBP2G260R mutants were generated using Q5 Site-Directed Mutagenesis Kit (NEB, E0554). 
FBP24KA Forward primer: 5’- caggagcgatttacagcctgaatgag-3’, Reverse primer: 5’- 
ccgccgcaatcttgacatctttttccac-3’. FBP2G260R Forward primer: 5’-cctggtctatagaggaatcttcctgtaccc-3', 
Reverse primer: 5'-gtgcggtgcacgtcagcc-3'.   
RNA Interference 
    LPS246 cells were plated in 6-well plate at a density of 2.5 × 105 cells per well. siRNA pools 
targeting human c-Myc (sc-29226) was obtained from Santa Cruz Biotechnology and non-targeting 
pool control (D-001810-10-05) was obtained from Dharmacon. For each well, 100 µl OPTI-MEM 
(Thermo Fisher Scientific, 31985062), 24 µl sic-Myc or non-targeting pool control (10 nM) and 12 
µl HiPerfect transfection reagent (Qiagen, 301705) were mixed and incubated before loaded to the 
plate.  
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Cell Growth Assays 
    Multiple cultures of LPS246, T1000, SW872, and KP250 cells were plated in 60 mm plates at a 
density of 8 × 104 cells supplemented with DMEM containing 1% FBS. Every other day, one set of 
cultures was collected and counted. Multiple cultures of LPS246, T1000, SW872, and HT1080 cells 
were plated in 60 mm plates at a density of 5 ×  104 cells with either glucose-free DMEM 
supplemented with 10% FBS and 5 mM D-(+)-Glucose (Sigma-Aldrich, G8270) or DMEM 
containing 10% FBS. Every day, one set of cultures was collected and counted every day.  
Anchorage-Independent Growth Assay 
    Sarcoma cells (SW872, HT1080, KP250) stably expressing FBP2 or vector control were plated 
in 6-well plates at a density of 6,000 cells per well in complete medium containing 0.3% agarose 
(low-melt 2-hydroxyethylagarose, Sigma-Aldrich, A4018), onto underlays composed of medium 
containing 0.6% agarose. Additional media was added to the cultures once per week, and after two 
weeks of growth the colonies were quantified. 
Western Blot Analysis 
Cells were harvested in lysis buffer (150 mM NaCl, 10 mM Tris pH 7.6, 0.1% SDS and 5 mM 
EDTA) containing Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 
78445). For western blots of xenograft tissue, approximately 20-30 mg of tissue was suspended in 
500 µl lysis buffer and homogenized on ice using a Tissue-Tearor (Biospec, 985370). Samples 
were centrifuged at 12,000 rpm for 20 min at 4 °C. Protein lysates were resolved by Tris-Glycine 
SDS-PAGE and were transferred to nitrocellulose membranes (Bio-Rad, 162-0115, 0.45 µm pore 
size for all experiments). All membranes were incubated with the indicated primary antibodies 
overnight at 4 °C and were diluted in TBST (20 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20) 
supplemented with 5% bovine serum albumin (BSA, Sigma-Aldrich, A7906). Primary antibodies 
were detected with horseradish peroxidase-conjugated secondary antibodies followed by exposure 
to ECL reagents. 
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Co-Immunoprecipitation 
LSP246 cells expressing FBP2 or FBP24KA were incubated in Co-IP lysis buffer (20 mM Tris HCl 
pH 8, 137 mM NaCl, 1% NP-40 and 2 mM EDTA) supplemented with Halt Protease and 
Phosphatase Inhibitor Cocktail for 20 min at 4 °C. Collect the lysates and centrifuge at 12,000 rpm 
for 10 min at 4 °C. Transfer the supernatant to a clean tube and save 1/10 lysate as input. Pre-
clean the rest lysate by adding 50 µl Protein Agarose A/G bead slurry (Thermo Fisher Scientific, 
20421) and 2 µl mouse IgG (Cell Signaling Technology, #5415) and rotate at 4 °C for 2 hours. Spin 
down the beads. The lysates were evenly separated and incubated with IgG or V5 antibody 
(Thermo Fisher Scientific, #R960-25) at 4 °C overnight. 35 µl Protein Agarose A/G bead slurry was 
incubated with lysates for additional 2 hours. Wash the beads with Co-IP lysis buffer three times 
and add 2 × loading buffer (0.5 M Tris-HCl pH 6.8, 4.4% SDS, 20% glycerol, 2% 2-mercaptoethanol, 
0.1% bromophenol blue) to elute the bound proteins.  
GST pull-down 
The cDNA fragment of c-Myc was obtained from Addgene (102626) and was amplified and 
cloned into pGEX fusion with glutathione S-transferase (GST) as the bait using primers (F: CGC 
GGATCCATGGATTACAAGGATGACGACGATAAG, R: CCGGAATTCTTACGCACAAGAGTTCC 
GTAGCT). FBP2 cDNA construct: MHS6278-211687897 (Accession, BC117477) was cloned into 
pET-28a (+) plasmid as the prey for fusion with His-tag using the indicated primers (F: CGCGGATC 
CATGACGGACAGAAGCCCCTTC, R: CCGGAATTCTCAATGGTGATGGTGATGATGACCGG). 
Both bait and prey recombinant proteins were used to transform E. coli strain BL-21 for protein 
expression. Both bait and prey proteins were blocked using 4% BSA (final concentration 0.8%) at 
4 °C for 30 min. Combine both proteins with 60 µl Glutathione Sepharose 4B (17075601) and rotate 
at 4 °C for 2 hours. Wash beads twice with PBS + 0.5% NP-40, once with PBS + 0.5% NP-40 + 
300 mM KCl and twice with PBS + 0.5% NP-40. Resuspend the beads with 30 µl 2 × loading buffer 
and boil the samples at 95 °C for 10 min.  
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Quantitative RT-PCR 
    Total RNA was isolated from cells using the RNAeasy purification kit (Qiagen, 74104). cDNA 
was synthesized using a High Capacity RNA-to-cDNA kit (Applied Biosystems, 4368814). qRT-
PCR was performed on a ViiA7 Real-Time PCR system from Applied Biosystems. Pre-designed 
Taqman primers were obtained from Life Technologies for the following genes: 18S 
(HS03928985_G1), MT-ND1 (HS02596873_S1), MT-MYB (HS02596867_S1), MT-CO1 
(HS02596864_G1), and MT-ATP6 (HS02596862_G1), c-Myc (Hs00153408_m1), CCND2 
(Hs00153380_m1), eIF2A (Hs00230684_m1), NPM1 (Hs02339479_g1), PSAT1 
(Hs00795278_mH). 
Chromatin Immunoprecipitation (ChIP) and ChIP-reChIP Assay 
    ChIP and ChIP-reChIP were performed as described previously (Si et al., 2015). Briefly, cells 
were cross-linked using 1% formaldehyde at room temperature for 10 min. The cross-linking 
reaction was quenched by glycine. Cells were lysed in SDS buffer containing protease inhibitor 
cocktail and lysates were sonicated at 4 °C (30s on and 30s off, 15 cycles). The sheared chromatin 
was precleared, and then subjected to immunoprecipitation with 5 µg IgG (Cell Signaling 
Technology, 5415) and V5 (Thermo Fisher Scientific, R960-25) antibodies. After washing with low- 
and high-salt buffers, immunoprecipitated DNA fragments were eluted and purified with the 
QIAquick PCR Purification Kit and then analyzed by qRT-PCR. For ChIP-reChIP, the first ChIP was 
performed using c-Myc antibody (Santa Cruz Biotechnology, sc-40x), until the washing steps. The 
immunoprecipitated protein-DNA complexes were incubated in ChIP-reChIP elution buffer (10 mM 
Tris-HCl, pH 8.0, 2 mM EDTA, 2% SDS, 15 mM DTT, supplemented with protease inhibitor cocktail) 
for 30 min at 37 °C. The isolated supernatant was diluted at least 20 times and subjected to the 
second ChIP using 5 µg IgG or V5 antibodies.  
mtDNA Content 
    Total DNA was extracted from cell samples using Wizard Genomic DNA Purification Kit 
(Promega, A1120) according to the manufacturer’s instructions. To quantify mtDNA copy number, 
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real-time PCR was performed using a on a ViiA7 Real-Time PCR system from Applied Biosystems 
against MT-ND1 (HS02596873_S1) as the standard for mtDNA. The b-globin (HBB) was used as 
the nuclear gene (nDNA) normalizer for calculation of the mtDNA/nDNA ratio, as previously 
described (Dickinson et al., 2013).  A fragment of HBB gene was amplified using forward primer, 
5’-caacttcatccacgttcacc-3’, and reverse primer, 5’-gaagagccaaggacaggtac-3’. The relative mtDNA 
content was calculated using the formula: mtDNA content = 1/2DCt, where DCt = CtmtDNA − CtHBB.  
Subcellular Fractionation 
Cytosolic and nuclear fractionation of indicated cells were performed using NE-PER nuclear and 
cytoplasmic extraction reagents (Thermo Fisher Scientific, 78833) by following the manufacturer’s 
protocol. Briefly, cells were trypsinized, washed using PBS and pelleted. Depending on the volume 
of cell pellet, the ratio of CER I, CER II and NER were maintained at 200:11:100 µl (for 20 µl cell 
pellet). Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, 78445) was 
added to CER I and NER. Cells were first incubated with CER I for 10 min, followed by CER II for 
1 min and centrifuged at 12,000 rpm for 5 min at 4 °C. The supernatant was saved as cytoplasmic 
extract and the insoluble fraction was suspended in NER. Vortex for 15s every 10 min, for a total 
of 40 min. Centrifuge at 12,000 rpm for 10 min at 4 °C and the supernatant is the nuclear extract.  
FBP2 Enzymatic Activity Assay 
    Vector control 293T cells, or 293T cells expressing FBP2, FBP24KA or FBP2G260R were harvested 
in lysis buffer used for western blot analysis. 20 µg lysates were added to 100 µl reaction buffer 
containing 50 mM Tris (pH 6.8), 10 mM MgCl2, and 100 µM D-fructose 1,6- bisphosphate trisodium 
salt (Sigma-Aldrich, F6803). The reaction was started by incubating solutions at 37 °C for 15 min 
and stopped by a deproteinization protocol using Deproteinizing Sample Preparation Kit (BioVision, 
K808). FBP2 catalytic activity was quantified according to the yield of fructose 6-phosphate 
(enzyme product), measured by Fructose-6-Phosphate Fluorometric Assay Kit (BioVision, K689-
100). 
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Cell Apoptosis Assay 
    LPS246 TetO-FBP2 (PBS or Dox treated) and LPS246 TetO-FBP24KA (PBS or Dox treated) cells 
were seeded in 6-well plates at a density of 1.5 × 105 per well. These cells were incubated in 5 mM 
glucose medium (glucose-free DMEM, 10% FBS, 5 mM glucose) or 5 mM galactose medium 
(glucose-free DMEM, 10% FBS, 5 mM galactose). After 24 h, cells and supernatant were collected 
and centrifuged. The cell pellet was suspended with 110 µl binding buffer. Cells were then stained 
with the FITC-Annexin V Apoptosis Detection Kit (BD Biosciences, 556547) with Annexin V Alexa 
Fluor 488 and propidium iodide (PI) and incubated for 15 min at room temperature in the dark. After 
incubation, 400 µl of binding buffer was added and cells were analyzed by flow cytometry using the 
BD Accuri C6 instrument. Double-negative cells were determined viable.  
MitoTracker and MitoSox Staining 
    LPS246 TetO-FBP2 (PBS or Dox treated) and LPS246 TetO-FBP24KA (PBS or Dox treated) cells 
were seeded in 6-well plates at a density of 1.5 × 105 per well. Cells were incubated with 5 µM 
MitoSox reagent (Thermo Fisher Scientific, M36008) or 25-100 nM MitoTracker Green FM probe 
(Thermo Fisher Scientific, M7514) at 37 °C for 30 min. Save one well of cell without staining as the 
negative control. After staining was complete, the cells were gently washed three times with warm 
PBS. Detach cells from plates and ensure a single cell suspension. Analyze the samples by flow 
cytometry using BD Accuri C6. 
ATP Measurements 
    ATP production was measured using the ATP Determination Kit (Thermo Fisher Scientific, 
A22066) according to the manufacturer’s protocol. Briefly, cells were homogenized in lysis buffer 
(1% Triton X-100, 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl pH 7.5) supplemented with protease 
and phosphatase inhibitor cocktail (Thermo Fisher Scientific, 78445). Data were determined by 
luminescence (Promega, Glomax 20/20 luminometer). Data were collected from multiple replicate 
wells for each experiment and were normalized to protein concentration.  
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Citrate Synthase Activity 
    Citrate synthase activity was measured on total cell extracts by Citrate Synthase Activity Assay 
Kit (Abcam, ab119692). In brief, 100 µl of cell lysates was added to the pre-coated microplate strips, 
sealed, and incubated at room temperature for 3 hours. The wells were aspirated and washed twice 
with 300 µl wash buffer. Activity solution was added to the well and the plate was immediately read 
every 20 seconds for 30 min at a wavelength of 412 nm using a plate reader (BioTek, Synergy H1).  
Immunohistochemistry  
    LPS246 tumor sections and tissue microarray slides (US Biomax, SO801b) were deparaffinized 
by baking slides at 60 °C for 30 min. The slides were rehydrated in series of ethanol solutions and 
endogenous peroxidase activities were quenched by 1% H2O2 in distilled water for 20 min. After 
three washes in TT buffer (500 mM NaCl, 10 mM Trizma, and 0.05% Tween-20), antigen retrieval 
was performed by boiling slides for 20 min in a citrate-based antigen unmasking solution (Vector 
labs, H3300). After cooling down to room temperature, slides were blocked in 2% normal goat 
serum and 4% BSA in TT buffer for 1 h. Next, tissue slides were incubated with various primary 
antibodies at 4 °C overnight. After three washes in TT buffer, biotinylated secondary antibody was 
added onto these slides for 1 h, following by 1 h treatment of the Vectastain Elite ABC reagents 
(Vector Labs, PK-6100). After three TT washes, the slides were processed with DAB peroxidase 
substrate kit (Vector Labs, SK-4100), and hematoxylin solutions for immunohistochemistry staining, 
dehydrated in a standard ethanol/xylene series, and mounted in 75% v/v Permount (Fischer 
Scientific, SP15-500) in xylenes.  
Tissue Immunofluorescence   
    LPS246 tumors were fixed in 4% paraformaldehyde (PFA)/PBS overnight at 4 °C. Fixed tissues 
were dehydrated in 30% sucrose solution and embedded in OCT for frozen sectioning. Tissue 
samples were submitted to the Molecular Pathology & Imaging Core (MPIC) at the University of 
Pennsylvania for processing and sectioning. Frozen sections were rinsed in cold PBS to remove 
OCT, and then incubated with 0.25% Triton-X-100 in PBS for 10 min at room temperature. The 
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slides were incubated in a blocking buffer (4% BSA, 2% serum in PBS) for 1 h at room temperature. 
The slides were then incubated with diluted primary antibodies in blocking buffer overnight at 4 °C. 
After washing in PBS, the slides were further incubated with fluorescein-conjugated secondary 
antibodies diluted in blocking buffer for 1 hour at room temperature. The slides were finally mounted 
with ProLong Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific, P36962). Slides 
were examined and images were captured on a Leica DM5000B microscope.   
Cell Immunofluorescence 
    Cells were plated in 2-well Chamber Slides (Lab-Tek, 154461). After 24 h, the cells were washed 
three times with PBS and fixed for 20 min in 4% paraformaldehyde at room temperature. Cells were 
permeabilized in PBS containing 0.5% Triton X-100 and blocked in PBS containing 5% BSA 
(blocking buffer). Primary antibodies against FBP2 (Abcam, ab131253) and secondary antibodies 
(Thermo Fisher Scientific, Alexa Fluor 488) were diluted in blocking buffer. Slides were washed 
three times in PBS, rinsed in H2O, and mounted on slides using VectaShield mounting medium 
containing 4’6’-diamidino-2-phenylindole (DAPI) (Vector Labs, H-1200). 
Metabolic Quantification 
    The rate of glucose uptake and lactate secretion was determined using Multiparameter 
Bioanalytical System (YSI Life Sciences, YSI 2950). Briefly, cells were seeded in 6 cm plates 
starting with 4 replicates. The next day, the medium was changed to 10 mM glucose medium 
(glucose-free and glutamine-free DMEM, 10% dialyzed FBS, 10 mM glucose, 2 mM glutamine). 
Cells in one replicate ware trypsinized and counted. The cell number was labeled as Q1 (starting 
cell number). 24 h later, culture medium was collected and read by YSI analyzer. Cell number was 
counted as Q2 (final cell cell number). Measurements were normalized to cell number area under 
the curve, as previously described (Gentile et al., 2013). Metabolite consumption was defined 
as v = V(xmedium control − xfinal)/A, where v is metabolite consumption/production, V is culture 
volume, x is metabolite concentration, and A is cell number area under the curve. A was calculated 
as N(T)d/ln2(1 − 2−T/d), where N(T) is the final cell count, d is doubling time, and T is time of 
experiment. Doubling time was calculated as d = (T)[log(2)/log(Q2/Q1)]. 
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13C-metabolic Flux Analysis 
    Cells were seeded to 10 cm plates at a density of 1 million cells per plate. For [1,2-13C]glucose 
labeling, cells were incubated in 10 mM [1,2-13C]glucose medium (glucose-free DMEM, 10% FBS, 
10 mM [1,2-13C]glucose) for 24 h. For [3-13C]pyruvate labeling, cells were incubated in 2 mM [3-
13C]pyruvate medium (glucose-free DMEM, 10% FBS, 2 mM [3-13C]pyruvate) for 6 h. To measure 
the 13C enrichment in TCA cycle intermediates, [1,2-13C]glucose-labelled or [3-13C]pyruvate-
labelled cells were extracted by 4% perchloric acid (PCA). Briefly, cells were washed twice with 
ice-cold PBS and then scraped in 4% PCA on dry ice, which was then freeze-thawed for three 
cycles. Cell extracts were neutralized using 5 M KOH and analyzed as previously described (Nissim 
et al., 2012). The neutralized PCA extract were subjected to an AG-1 column (100-200 mesh, 0.5 ×	2.5 cm, Bio-rad) for enriching the organic acids, glutamate and aspartate, which were then 
converted to t-butyldimethylsilyl derivatives. The production of 13C-labeled metabolites was 
measured using GC-MS. Isotopic enrichment in [13C]glutamate isotopomers was monitored using 
ions at m/z 432, 433, 434, 435, 436 and 437 for M0, M1, M2, M3, M4 and M5 (containing 1 to 5 13C 
atoms above M0, the natural abundance), respectively. Isotopic enrichment in [13C]aspartate 
isotopomers was monitored using ions at m/z 418, 419, 420, 421 and 422 for M0, M1, M2, M3 and 
M4 (containing 1 to 4 13C atoms above M0, the natural abundance), respectively. Isotopic 
enrichment in [13C]lactate was determined using ions at m/z 261, 262, 263 and 264 for M0, M1, M2 
and M3 (containing 1 to 3 13C atoms above natural abundance), respectively. Isotopic enrichment 
in [13C]pyruvate isotopomers was monitored using ions at m/z 259, 260, 261 and 262 for M0, M1, 
M2 and M3 (containing 1 to 3 13C atoms above M0, the natural abundance), respectively. Isotopic 
enrichment in [13C]malate isotopomers was monitored using ions at m/z 419, 420, 421, 422 and 
423 for M0, M1, M2, M3 and M4 (containing 1 to 4 13C atoms above M0, the natural abundance), 
respectively, and 13C enrichment in [13C]citrate isotopomers was assayed using ions at m/z 459, 
460, 461, 462, 463, 464 and 465 for M0, M1, M2, M3, M4, M5 and M6 (containing 1 to 6 13C atoms 
above M0, the natural abundance), respectively. 
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Quantification of the Pentose Phosphate Pathway (PPP) 
    Metabolic flux going through the PPP was quantified as previously described (Lee et al., 1998), 
using [1,2-13C]glucose as the labelling tracer. Briefly, direct glycolysis of [1,2-13C]glucose (without 
going through the PPP) produces M2-labelled lactate, while flux going through the oxidative portion 
of PPP removes the first carbon from glucose and releases it in the form of CO2. The resultant M1-
labelled intermediates are recycled back to glycolysis to produce M1-labelled lactate through the 
non-oxidative potion of PPP. The ratio of M1 to M2-labelled lactate indicates the ratio of flux going 
through the PPP versus flux directly going through glycolysis. Therefore, PPP flux was calculated 
based on the following formula: PPP flux = glucose consumption × M1 lactate enrichment / (M1 
lactate enrichment + M2 lactate enrichment). Calculated PPP flux was then normalized to vector 
control cells by setting the vector control flux equal to 1. 
Seahorse XF Cell Mito Stress Analysis 
    The mitochondrial respiratory capacity was determined using XF Cell Mito Stress Test Kit 
(Agilent Technologies, 103015-100). Cells were seeded in the XF96 Cell Culture Microplate at a 
density of 2 ×	104 cells per well. 6 replicates were set up for each of the following groups: (1) 
LPS246 TetO-FBP2 + Veh; (2) LPS246 TetO-FBP2 + Dox; (3) LPS246 TetO-FBP24KA + Veh; (4) 
LPS246 TetO-FBP24KA + Dox. Microplate was incubated for 24 h at 37 °C. Seahorse XF96 FluxPak 
sensor cartridge was hydrated in the utility plate filled with 200 µl of Seahorse Calibrant overnight 
in a non-CO2 incubator at 37 °C. Next day, cells were incubated with the base medium containing 
2 mM L-glutamine, 1 mM sodium pyruvate, and 10 mM glucose for 1 hour prior to assay. The 
oxygen consumption rate (OCR) was measured by XFe96 extracellular flux analyzer with 
sequential injection of 1 µM oligomycin A, 1 µM FCCP, and 0.5 µM rotenone/antimycin A. After the 
experiment, cells lysates were harvested with 20 µl western blot lysis buffer and protein 
concentration was quantified using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, 23225). 
OCR value was normalized to the protein concentration in each well.  
 20 
 
Quantification and Statistical Analysis 
All statistical analyses were conducted using GraphPad Prism 7.0. All error bars are presented as 
mean ± s.d. unless otherwise specified. Data were reported as biological replicates. P values were 
calculated based on two-tailed, unpaired Student’s t-tests. Significance was defined as *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Table 2. Key resources table. 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit monoclonal anti-FBP2 Abcam #ab131253 
Rabbit polyclonal anti-FBP2 for IHC Sigma-Aldrich #HPA012513 
Mouse polyclonal anti-FBP1  Sigma-Aldrich #SAB1405798 
Rabbit polyclonal anti-PCK1 Abcam #ab28455 
Rabbit polyclonal anti-G6PC Abcam #ab83690 
Rabbit monoclonal anti-GAPDH Cell Signaling Technology #2118 
Mouse monoclonal anti-HDAC1  Cell Signaling Technology #5356 
Rabbit monoclonal anti-HSP90 Cell Signaling Technology #4877 
Rabbit polyclonal anti-Phospho-Histone H3 Cell Signaling Technology #9701 
Anti-rabbit IgG HRP-linked Cell Signaling Technology #7074 
Anti-mouse IgG HRP-linked Cell Signaling Technology #7076 
Mouse (G3A1) mAb IgG1 Isotype Control Cell Signaling Technology  #5415 
Normal Rabbit IgG Cell Signaling Technology #2729 
NRF1 (D9K6P) Rabbit mAb Cell Signaling Technology #46743 
Rabbit monoclonal anit-VDAC1 ABclonal #A11242 
Rabbit polyclonal anti-TOMM20 ABclonal #A6774 
TFAM Polyclonal Antibody ABclonal #A13552 
Biotinylated Goat anti-Rabbit IgG  Vector Labs #BA-1000 
Mouse monoclonal anti-V5 Tag Thermo Fisher Scientific #R960-25 
Goat anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor 488 conjugated 
Thermo Fisher Scientific #A-11008 
c-Myc Monoclonal Antibody (9E10) Thermo Fisher Scientific #13-2500 
 
Biological Samples   
Soft tissue malignant tumor tissue array US Biomax SO801b 
 
Chemicals, Peptides, and Recombinant Proteins 
DMEM Life Technologies 11965-084 
Glucose-free DMEM Life Technologies 11966-025 
Glucose-free and glutamine-free DMEM Life Technologies A1443001 
L-Glutamine Life Technologies 25030-081 
Sodium Pyruvate Life Technologies 11360-070 
Horse serum Life Technologies 16050-122 
Standard FBS Gemini 900-108 
Dialyzed FBS Gemini 100-108 
HSMM cell growth media (SkGM-2 BulletKit) Lonza CC-3245 
[1,2-13C]glucose Sigma-Aldrich 453188 
[3-13C]sodium pyruvate Sigma-Aldrich 490733 
D-(+)-Glucose Sigma-Aldrich G8270 
D-(+)-Galactose Sigma-Aldrich G0750 
D-fructose 1,6-bisphosphate trisodium salt 
hydrate 
Sigma-Aldrich F6803 
Perchloric acid, 70% Sigma-Aldrich 311421 
Polybrene Sigma-Aldrich 107689 
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Doxycycline hydrochloride Sigma-Aldrich D3447 
2-Hydroxyethyl agarose Sigma-Aldrich A4018 
Bovine serum albumin Sigma-Aldrich A7906 
MitoSox Thermo Fisher Scientific M36008 
Hoechst Thermo Fisher Scientific 62249 
MitoTracker Green FM Thermo Fisher Scientific M7514 
Propidium Iodide Thermo Fisher Scientific P3566 
ProLong Diamond Antifade Mountant with 
DAPI 
Thermo Fisher Scientific P36962 
Halt Protease and Phosphatase Inhibitor 
Cocktail 
Thermo Fisher Scientific 78445 
FuGENE 6 Transfection Reagent Promega E2691 
Seahorse XFe96 FluxPaks  Agilent 102601-100 
Seahorse XF Base Medium Agilent 102353-100 
Matrigel matrix Corning 356234 
Glutathione Sepharose 4B resin GE Healthcare 17075601 
Doxycycline diet - Sterile Bio-Serv S3888 
Control diet - Sterile Bio-Serv S4207 
 
Critical Commercial Assays 
Seahorse XF Cell Mito Stress Test Kit Agilent 103015-100 
Seahorse XF Glycolysis Stress Test Kit Agilent 103020-100 
Citrate Synthase Activity Assay Kit Abcam ab119692 
FITC Annexin V Apoptosis Detection Kit BD Biosciences 556547 
Deproteinizing Sample Preparation Kit BioVision K808 
Fructose-6-Phosphate Fluorometric Assay 
Kit  
BioVision K689-100 
Nuclear and Cytoplasmic Extraction 
Reagents 
Thermo Fisher Scientific 78833 
ATP Determination Kit Thermo Fisher Scientific A22066 
Q5 Site-Directed Mutagenesis Kit New England BioLabs E0554 
Wizard Genomic DNA Purification Kit Promega A1120 
RNeasy Mini Kit Qiagen 74104 
High-Capacity cDNA Reverse Transcription 
Kit 
Applied Biosystems 4368814 
 
Experimental Models: Cell Lines 
293T ATCC CRL-3216 
HT1080 ATCC CCL-121 
C2C12 ATCC CRL-1772 
SW872 ATCC HTB-92 
LPS224 Core Facilities, MD 
Anderson Cancer Center, 
Houston, TX 
A gift from Dr. 
Dina Lev 
LPS246 Core Facilities, MD 
Anderson Cancer Center, 
Houston, TX 
A gift from Dr. 
Dina Lev 
T449 Established from a well-
differentiated liposarcoma 
CVCL_M807 
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T778 Established from a well-
differentiated liposarcoma 
CVCL_M808 
T1000 Established from a well-
differentiated liposarcoma 
CVCL_M809 
KP250 Derived from UPS mouse 
tumor  
 
HSMM Lonza CC-2580 
 
Experimental Models: Organisms/Strains 
NOD-scid IL2Rgammanull mice The Jackson Laboratory 005557 
 
Oligonucleotides 
18S Life Technologies HS03928985_G1 
MT-ND1 Life Technologies HS02596873_S1 
MT-MYB Life Technologies HS02596867_S1 
MT-CO1 Life Technologies HS02596864_G1 
MT-ATP6 Life Technologies HS02596862_G1 
TFAM Life Technologies Hs00273372_s1 
NRF1 Life Technologies Hs00602161_m1 
c-Myc Life Technologies Hs00153408_m1 
CCDN2 Life Technologies Hs00153380_m1 
eIF2A Life Technologies Hs00230684_m1 
NPM1 Life Technologies Hs02339479_g1 
PSAT1 Life Technologies Hs00795278_mH 
c-Myc siRNA Santa Cruz Biotechnology sc-29226 
ON-TARGETplus Non-targeting Pool Dharmacon D-001810-10-05 
b-globin (genomic DNA) 
Forward: caacttcatccacgttcacc  
Reverse: gaagagccaaggacaggtac 
(Dickinson et al., 2013)  
 
Recombinant DNA 
pCDH-CMV-MCS-EF1-Puromycin System Biosciences CD510B-1 
pLVX-TetOne-Puro Clontech 631847 
pLV-EF1a-IRES-Blast Addgene 85133 
pGEX  A gift from Dr. 
Xiaolu Yang 
pET-28a (+)  A gift from Dr. 
Xiaolu Yang 
FBP2 cDNA Dharmacon MHS6278-
211687897 
TFAM cDNA Dharmacon MHS6278-
211689190 
NRF1 cDNA Dharmacon MHS6278-
202757860 
 
Software and Algorithms 
GraphPad Prism 7.0 GraphPad Software http://www.graph
pad.com 
ImageJ NIH https://fiji.sc 
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FlowJo FlowJo https://www.flowj
o.com/solutions/fl
owjo 
 
Other 
Seahorse XFe96 Analyzer Agilent  
YSI 2950 YSI  
Tissue Tearor Biospec 985370 
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CHAPTER 3 RESULTS 
FBP2 is frequently lost in soft tissue sarcomas 
To assess their potential role in regulating sarcoma cell glucose metabolism, we measured the 
expression levels of three rate-limiting gluconeogenic enzymes, glucose-6-phosphatase catalytic 
subunit (G6PC), phosphoenolpyruvate carboxykinase 1 (PCK1), and fructose-1,6-bisphosphatase 
(FBP) using published microarray data from human STS (Barretina et al., 2010; Detwiller et al., 
2005). As previously reported (Mizunuma and Tashima, 1990; Tejwani, 1983), FBP1 is the 
predominant isozyme in liver, kidney and small intestine (Figure 1A), whereas FBP2 expression 
predominates in muscle (Figure 1B). Further analysis revealed that FBP2 mRNA levels are 
significantly reduced in liposarcoma, fibrosarcoma, leiomyosarcoma, and UPS samples relative to 
either normal skeletal muscle (Figure 2A) or adipose tissue (Figure 2B). Moreover, mouse UPS 
tumors isolated from a previously described autochthonous “KP” (LSL-KrasG12D/+; Trp53fl/fl) model 
(Kirsch et al., 2007; Mito et al., 2009) exhibited decreased FBP2 immunostaining relative to 
adjacent skeletal muscle tissue (Figure 2C). FBP2 protein abundance was also decreased in a 
variety of human sarcoma and mouse UPS cell lines, relative to mesenchymal stem cell (MSC) and 
human skeletal muscle myoblast (HSMM) or mouse C2C12 myoblasts (Figure 2D). Analysis of a 
representative human sarcoma tissue array showed undetectable FBP2 protein accumulation, 
compared to normal mesenchymal tissue, in almost 100% of sarcoma tumors examined (n = 70, 
Figure 3A-C). Even though FBP2 expression is widely repressed in STS, intertumoral heterogeneity 
still results in different levels of repression among sarcoma samples, and a liposarcoma data set 
(Gobble et al., 2011) revealed that lower FBP2 mRNA levels correlated with worse overall survival 
in liposarcoma patients (Figure 3D). We concluded that FBP2 loss is a common feature in STS 
subtypes and may contribute directly to tumorigenesis.   
    In contrast to FBP2, G6PC and PCK1 mRNA levels were similar in liposarcoma, fibrosarcoma, 
leiomyosarcoma, and other sarcoma subtypes compared with normal skeletal muscle (Figure 4A-
C), and liposarcoma cell lines exhibited PCK1 and G6PC protein abundance comparable to control 
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MSCs (Figure 4D).  FBP1 was undetectable in tumors and sarcoma cell lines of diverse histological 
subtypes or controls, including MSC and human skeletal muscle myoblast (HSMM) (Figure 4E-F).  
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Figure 1. Differential tissue distribution of FBP1 and FBP2. 
(A and B) FBP1 (A) and FBP2 (B) mRNA expression in multiple normal tissues and a variety of 
human sarcoma samples. Fibrosarc, fibrosarcoma; Lipo.dediff, dedifferentiated liposarcoma; 
Lipo.pleo, pleomorphic liposarcoma; Lipo.round, round cell liposarcoma; MFH, malignant fibrous 
histiocytoma.  
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Figure 2. FBP2 is severely downregulated in a variety of sarcomas. 
(A and B) FBP2 mRNA expression from Oncomine analysis of the (A) Detwiller et al. and (B) 
Barretina et al. sarcoma patient samples data set (Barretina et al., 2010; Detwiller et al., 2005). 
Values are normalized to median-centered intensity and shown on a log2 scale. Abbreviations: 
dediff. lipo., dedifferentiated liposarcoma; MFH, malignant fibrous histiocytoma; MFH/Pleo., UPS; 
pleomorphic lipo., pleomorphic liposarcoma; RC lipo., round cell liposarcoma. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001; n.s., not significant.  
(C) Representative immunohistochemical (IHC) staining of FBP2 in mouse UPS tumor and 
surrounding muscle. Scale bars: 100 µm. 
(D) Immunoblot analysis of FBP2 protein level in various human (left) and mouse (right) sarcoma 
cell lines. MSC, HSMM and C2C12 served as normal control. MSC, mesenchymal stem cell; HSMM, 
human skeletal muscle myoblast; (N), normoxia; (H) hypoxia; D-, differentiated; LMS, 
leiomyosarcoma; RD, rhabdomyosarcoma; FS, fibrosarcoma. GAPDH served as loading control. 
 
 29 
 
 
 
 
 
Figure 3. FBP2 protein abundance is uniformly decreased in sarcoma patient samples. 
(A) Representative IHC FBP2 staining in human muscle and sarcoma samples from human 
sarcoma tissue array, including fibrous histiocytoma, liposarcoma, neurilemmoma, and 
leiomyosarcoma. Scale bars: 100 µm. 
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(B) Immunohistochemistry staining of a representative sarcoma microarray with FBP2 antibody. T, 
sarcoma tumor tissues; N, normal counterparts. Red box indicates normal counterparts. The 
sarcoma type of each sample is listed below.  
(C) Quantification of IHC staining of 70 sarcomas and 10 normal tissues with FBP2 antibody from 
(B). 
(D) Kaplan–Meier curve of overall survival of liposarcoma patients from the Gobble et al. data set 
(Gobble et al., 2011), segregated into the top 33% FBP2 expression (High FBP2, n = 32), middle 
33% FBP2 expression (Medium FBP2, n = 32), and bottom FBP2 expression (Low FBP2, n = 32). 
The p-value was calculated using a log-rank (Mantel–Cox) test. 
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Figure 4. The expression of other gluconeogenic enzymes exhibit no consistent change in 
sarcoma.  
(A) Illustration of central carbon metabolism, including glycolysis, gluconeogenesis, pentose 
phosphate pathway, and the TCA cycle. Enzymes controlling glycolysis (HK, hexokinase; PFK, 
phosphofructokinase; PKM, pyruvate kinase type M) are highlighted in orange, while enzymes 
controlling gluconeogenesis (G6PC, glucose-6-phosphatase catalytic subunit; FBP, fructose-1,6-
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bisphosphatase; PCK, phosphoenolpyruvate carboxykinase) are highlighted in green. G6P, 
glucose-6-phosphate; F6P, fructose 6-phosphate; F-1,6-BP, fructose 1,6-bisphosphate; DHAP, 
dihydroxyacetone phosphate; GAP, glyceraldehyde 3-phosphate; R5P, ribose 5-phosphate; X5P, 
xylulose 5-phosphate; PEP, phosphoenolpyruvate; Pyr, pyruvate; Lac, lactate; Cit, citrate; aKG, a-
ketoglutarate; Glu, glutamate; Mal, malate; Oac, oxaloacetate; Asp, aspartate. 
(B and C) G6PC (B) and PCK1 (C) mRNA expression based on Oncomine analysis of the Detwiller 
et al. sarcoma patient samples data set (Detwiller et al., 2005). Values are normalized to median-
centered intensity and shown on a log2 scale. Dediff. lipo., dedifferentiated liposarcoma; MFH, 
Malignant Fibrous Histiocytoma; pleomorphic lipo., pleomorphic liposarcoma; RC lipo., round cell 
liposarcoma.  
(D) Immunoblot analysis of PCK1 and G6PC protein levels in various human sarcoma cell lines. 
MSC, mesenchymal stem cells. MSCs served as normal control, while GAPDH served as a loading 
control.  
(E) FBP1 mRNA expression based on Oncomine analysis of the Detwiller et al. sarcoma patient 
samples data set (Detwiller et al., 2005). 
(F) Immunoblot analysis of FBP1 protein levels in various human sarcoma cell lines. MSC, 
mesenchymal stem cell; hep, human primary hepatocyte. MSC served as normal control and Hep 
served as positive control for FBP1 expression. GAPDH served as a loading control. * indicates 
non-specific band.  
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FBP2 Re-Expression Suppresses Sarcoma Growth 
To investigate its functional effects in different STS subtypes, we expressed FBP2 ectopically in 
human liposarcoma (LPS246, T1000, SW872), fibrosarcoma (HT1080), and mouse UPS (KP250) 
cell lines to levels observed in control HSMM or C2C12 cells, respectively (Figure 5A-B). FBP2 
significantly inhibited cell proliferation under either low serum (1% serum, 25 mM glucose) or low 
glucose (10% serum, 5 mM glucose) conditions (Figures 6A-B), reminiscent of nutrient starved 
tumor microenvironments, as well as replete culture conditions (Figures 6C). In addition, FBP2 re-
expression in SW872, HT1080 and KP250 cells dramatically impaired anchorage-independent 
growth in 3D soft agar colony assays (Figure 7).  
We also exploited a doxycycline (dox)-inducible system to restore FBP2 expression in LPS246 
cells (LPS246 TetO-FBP2) and identified dox concentrations that produced FBP2 protein in 
LPS246 TetO-FBP2 cells comparable to control HSMM cells (Figure 8A). To further evaluate the 
role of FBP2 in tumor growth and maintenance in vivo, NSG mice were injected subcutaneously 
with LPS246 TetO-FBP2 cells and tumors allowed to grow to 100 mm3. Subsequent dox-induced 
FBP2 expression decreased tumor growth (volume and mass) without affecting mouse body weight 
(Figure 8B-E). FBP2 expression was maintained during dox treatment as shown by western blot 
(Figure 8F) and immunohistochemistry (IHC) (Figure 8G). The FBP2-expressing tumor cohorts 
exhibited decreased tumor cell proliferation as indicated by decreased phospho-histone H3 staining 
(Figure 8H). These results demonstrate that FBP2 restoration inhibits the in vitro proliferation and 
in vivo tumor growth of multiple STS cell types, including UPS, fibrosarcoma and liposarcoma.  
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Figure 5. Re-expression of FBP2 in multiple sarcoma cell lines. 
(A and B) Immunoblot showing FBP2 expression levels over lentiviral titration in LPS246, T1000, 
SW872 and HT1080 cells compared to HSMM (A), and in KP250 cells compared to C2C12 (B). 
GAPDH served as a loading control. Arrows indicate virus volumes used for all experiments.  
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Figure 6. FBP2 re-expression inhibits sarcoma cell proliferation. 
(A) Growth of LPS246, T1000, SW872, and KP250 cells in low serum medium (1% FBS), with or 
without ectopic FBP2 expression. 
(B) Growth of LPS246, T1000, and HT1080 cells in low glucose medium (glucose free DMEM 
supplemented with 10% FBS and 5 mM glucose) with vector control of FBP2 expression. 
(C) Growth of LPS246, SW872, and HT1080 cells in replete medium (10% FBS and 25 mM glucose) 
with vector control of FBP2 expression.  
n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Figure 7. FBP2 re-expression inhibits anchorage independent growth. 
(A-C) Soft agar colony formation assay of SW872 (A), HT1080 (B), and KP250 (C) cells with or 
without FBP2 expression. Representative pictures of colony size (left) and quantification of colony 
number (right).  
Error bars represent SD of three replicate wells for each condition. *p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001. 
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Figure 8. Dox-induced FBP2 expression suppresses sarcoma progression. 
(A) Immunoblot showing FBP2 expression level with increased doxycycline concentration in 
LPS246 cells compared to HSMM. GAPDH served as loading control. The arrow indicates dox 
concentration used for all experiments. 
(B) Tumor volume of LPS246 TetO-FBP2 liposarcoma xenografts with or without dox-induced 
FBP2 expression (each group includes ten tumors from five mice). ****p < 0.0001. 
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(C and D) LPS246 xenograft tumor weight (C) and body weight (D) with or without dox treatment 
at time of euthanasia, measured in grams. ****p < 0.0001, n.s., not significant.  
(E) Representative xenograft tumors in mice fed with vehicle or dox chow.  
(F) FBP2 induction in xenograft tumors were validated by western blot. GAPDH served as loading 
control. 
(G) Representative immunohistochemistry image of FBP2 staining on LPS246 TetO-FBP2 tumor 
sections. Scale bars: 100 µm. Arrows indicate nuclear staining of FBP2.  
(H) Representative image (left) of immunofluorescent staining of phosphor-Histone 3 and 
quantifications (right) in xenograft tumors with or without dox treatment. Five fields per slide were 
quantified. Scale bars: 100 µm. Error bars represent SD of three experimental replicates. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not significant.  
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FBP2 Re-Expression Inhibits Glycolysis 
    Glucose metabolism is balanced by catabolic glycolysis/oxidative phosphorylation (OXPHOS) 
and anabolic gluconeogenesis/glycogen production. Since FBP2 is a rate-limiting enzyme in 
gluconeogenesis, FBP2 re-expression is likely to antagonize glycolysis and therefore reduce 
glucose uptake. We ectopically expressed FBP2 in five STS cell lines and examined glucose 
metabolism. FBP2 significantly decreased glucose uptake and lactate secretion without affecting 
glutamine uptake in LPS224, LPS246, T1000, HT1080, and KP250 cells cultured in 10 mM glucose 
(Figure 9A-C). To further assess glycolytic pathway, we investigated the metabolic fate of [1,2-
13C]glucose, which produces glycolytic and TCA cycle intermediates containing two 13C atoms, as 
well as intermediates containing one 13C atom from the pentose phosphate pathway (PPP) (Figure 
10A). Analysis of culture media confirmed reduced [1,2-13C]glucose uptake and M1- and M2-
labeled 13C-lactate secretion in FBP2-expressing LPS246 cells (Figure 10B-C), indicating 
decreased conversion of glucose to lactate. [1,2-13C]glucose releases its first carbon in the form of 
CO2 to generate M1 species when catabolized through the oxidative portion of PPP (Lee et al., 
1998); therefore, PPP flux can be determined by the ratio of M1- to M2-labeled lactate. Interestingly, 
we found that FBP2 re-expression reduced PPP flux (Figure 10D), which is important for the 
synthesis of ribonucleotides and NADPH. The same cell extracts were further analyzed by GC-MS 
to quantify M2 enrichment of glucose-derived TCA intermediates (citrate, a-ketoglutarate, fumarate, 
and malate), as well as TCA cycle products (aspartate and glutamate). We observed decreased 
M2 enrichment of four TCA intermediates (Figure 10E), as well as glutamate and aspartate (Figure 
10F) in FBP2-expressing cells.  
    In addition, we employed an unbiased approach to determine relative abundance of 
intermediates from glycolysis, serine metabolism and the TCA cycle in KP250 and HT1080 cells. 
In both cell lines, ectopic FBP2 expression significantly reduced steady-state abundance of 
metabolites in glycolysis (glucose-6-phosphate, pyruvate, lactate) (Figure 11A), serine metabolism 
(serine and glycine) (Figure 11B) and the TCA cycle (citrate, a-ketoglutarate, fumarate, malate, 
oxaloacetate) (Figure 11C). In contrast to these decreased metabolic intermediates in FBP2-
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expressing cells, we observed enrichment of metabolites in other pathways (Figure 11D), indicating 
a global metabolic adaptation in FBP2-expressing cells. Together, these results indicate that FBP2 
inhibits glycolysis, which further affects serine and TCA cycle metabolism.  
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Figure 9. FBP2 restoration opposes glycolysis in multiple sarcoma cell lines. 
(A-C) Glucose uptake (A), lactate secretion (B), and glutamine uptake (C) were assessed in 
LPS224, LPS246, T1000, HT1080, and KP250 cells with or without FBP2 re-expression by YSI 
bioanalyzer.  
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Figure 10. FBP2 re-expression inhibits glycolysis, the pentose phosphate pathway and 
glucose-derived TCA cycle. 
(A) Carbon fate map showing the isotopomer distribution of indicated metabolites derived from [1,2-
13C]glucose. 13C atoms are depicted as filled circles. 13C atoms directly going through the glycolytic 
pathway are colored in red, while 13C atoms going through the PPP and recycled back to glycolysis 
are colored in blue. 
(B and C) [1,2-13C]glucose consumption (B), M1 and M2 isotopomer distribution of lactate (C) 
measured from culture medium of LPS246 cells expressing vector control or FBP2.  
(D) Calculated PPP flux (relative to vector control) in LPS246 cells with or without FBP2 expression 
based on the M1 to M2 13C-lactate ratio in cell extracts.  
(E and F) M2 isotopomer distribution of indicated TCA metabolites (E) and amino acids (F) in 
LPS246 cells with or without FBP2 re-expression, labelled with [1,2-13C]glucose. M2 enrichment 
represents the mole per cent excess of M2 species above natural abundance. aKG, a-ketoglutarate.  
Values represent mean ± SD of three experimental replicates. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 11. Ectopic FBP2 expression opposes glycolysis and the TCA cycle. 
(A-C) Pan-metabolomic analysis of steady-state metabolites in KP250 cells (left) and HT1080 cells 
(right) expressing vector control or FBP2. Relative abundance of metabolites in glycolysis (A), 
serine metabolism (B) and TCA cycle (C) are shown.  
(D) Representative examples of metabolites whose relative abundance is higher in KP250 cells 
(left) or HT1080 cells (right) upon FBP2 restoration, compared to cells expressing control vector. 
Error bars represent SD of three experimental replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001. n.s., not significant.  
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Nuclear FBP2 Inhibits Mitochondrial Gene Expression 
    To investigate whether the growth inhibitory effect of FBP2 is dependent on its enzymatic activity, 
we generated a catalytically inactive FBP2 mutant by replacing a glycine residue at position 
260 with arginine (FBP2G260R) as previously described (Åsberg et al., 2010) (Figure 12A).  Upon 
wild-type FBP2 and FBP2G260R expression at comparable levels in LPS246 cells (Figure 12B), 
FBP2G260R inhibited cell growth, although to a lesser extent than wild-type FBP2 (Figure 12C), 
implying that FBP2 has catalytic activity-independent cellular functions.  
Accumulating evidence demonstrates that multiple glycolytic enzymes exhibit nuclear 
localization and interact with transcription factors to regulate gene expression, in addition to their 
cytoplasmic roles (Huangyang and Simon, 2018). Interestingly, we observed strong nuclear 
staining of FBP2 within xenograft tumor sections (Figure 13A), suggesting that FBP2 possesses 
nuclear function. Specifically, immunofluorescence indicated overlap between endogenous FBP2 
staining and DAPI staining in C2C12 cells (Figure 13B), and subcellular fractionation of HSMM and 
C2C12 cells further indicated that FBP2 co-purifies with both nuclear and cytosolic fractions (Figure 
13C). A nuclear localization sequence (NLS) (203KKKGK207) was previously identified in 
FBP2(Gizak et al., 2009a; 2009b). By replacing four lysine residues in the NLS with alanine, we 
generated a nucleus-excluded form of FBP2 without disrupting its catalytic activity (Figure 13D), 
and FBP24KA expression in LPS246 cells decreased cell proliferation albeit, not as dramatically as 
wild-type FBP2, suggesting that nuclear FBP2 contributes functionally to its growth inhibitory 
properties (Figure 13E-F). Interestingly, [1,2-13C]glucose labeling in control or FBP24KA-expressing 
cells determined that FBP24KA inhibits glucose uptake and lactate secretion (Figure 13G-H), but 
less potent than wild-type FBP2 (Figure 10B-C). These results indicate that nuclear FBP2 is also 
involved in suppressing glycolysis. 
    To gain further mechanistic insights into the function of nuclear FBP2, we compared the 
transcriptomes of vehicle (n = 5) or dox-treated (n = 4) LPS246 TetO-FBP2 cells by RNA-seq. Gene 
set enrichment analysis of FBP2-restored cells revealed reduced gene expression signatures for 
E2F targets, MYC targets, the G2M checkpoint, and OXPHOS (Figure 14A), as well as increased 
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expression signatures related to protein secretion, UV responses, and heme metabolism (Figure 
14B). Ingenuity Pathway Analysis (IPA) also identified OXPHOS and mitochondrial dysfunction as 
the primary differentially modulated pathways in FBP2-expressing cells, compared to controls 
(Figure 14C). These functional categories contain genes encoding essential subunits of 
mitochondrial complex I, III, IV and V of the electron transport chain and genes critical for 
mitochondrial function (UCP2 and RHOT2) (Figure 14D). We confirmed differential expression of 
several genes involved in OXPHOS (MT-ND1, MT-MYB, MT-CO1 and MT-ATP6) by qRT-PCR 
analysis and found that FBP2, but not FBP24KA, significantly decreased their expression (Figure 
15A). Intriguingly, catalytically inactive FBP2G260R downregulated mitochondrial gene expression to 
a similar level as wild-type FBP2 (Figure 15B). Taken together, these data suggest that nuclear 
FBP2 is required for inhibiting OXPHOS in an enzymatic activity-independent manner.  
 
  
 47 
 
 
Figure 12. Catalytically inactive FBP2G260R suppresses sarcoma cell growth. 
(A) Enzymatic activity in 293T cells expressing vector, wild-type FBP2 and FBP2G260R.  
(B) Protein levels of ectopically expressed FBP2 and FBP2G260R in LPS246 cells. GAPDH was used 
as a loading control.  
(C) Growth of vector control, FBP2- or FBP2G260R-expressing LPS246 cells grown in 1% serum 
medium. 
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Figure 13. Nuclear FBP2 is able to inhibit sarcoma cell proliferation and glycolysis. 
(A) Immunofluorescent staining of mouse myoblast C2C12 cells with FBP2 antibody. Asterisks 
indicate representative sites with nuclear FBP2. DAPI is a fluorescent nuclear dye. 
(B) FBP2 protein levels detected in cytosolic and nuclear fractions of C2C12 and HSMM. HSP90, 
a cytosolic protein, and HDAC1, a nuclear protein, reflect the purity of respective subcellular 
fractionations.  
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(C) Western blot analysis of V5-tagged FBP2 or FBP24KA (4 lysines in nuclear localization sequence 
were substituted with alanine) in the cytosolic and nuclear fractions of transfected LPS246 cells. 
(D) Enzymatic activity in 293T cells expressing control vector, wild-type FBP2 and FBP24KA.  
(E) Protein levels of ectopically expressed FBP2 and FBP24KA mutant in LPS246 cells. GAPDH 
serves as a loading control.  
(F) Growth of vector control, FBP2- or FBP24KA-expressing LPS246 cells in 1% serum medium. 
(G and H) [1,2-13C]glucose consumption (G), M1 and M2 isotopomer distribution of lactate (H) 
measured from culture medium of LPS246 cells expressing vector control or FBP2.  
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Figure 14. RNA-seq analyses of transcriptome between vehicle or dox treated LPS246 TetO-
FBP2 cells. 
(A and B) GSEA comparing vehicle-treated (n = 5) and dox-treated (n = 4) LPS246 TetO-FBP2 
cells. The 50-gene “Hallmark signatures” set from MsigDB was queried. Top 10 gene sets 
downregulated (A) or upregulated (B) in dox-treated groups are shown with the normalized 
enrichment score (NES). Relevant gene sets are highlighted with red.  
(C) Differentially expressed genes were analyzed using ingenuity pathway analysis (IPA) software. 
Top 10 relevant and significant biological pathways were identified according to p-value from 
Fisher’s exact test.  
(D) Heatmap showing the relative expression of OXPHOS genes and mitochondrial dysfunction 
pathway from IPA. Expression signals are depicted using pseudocoloring, in which expression for 
each gene is shown as high (red) or low (blue). 
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Figure 15. Nuclear FBP2 inhibits mitochondrial gene expression in a catalytic activity-
independent manner. 
(A) qRT-PCR analysis of MT-ND1, MT-CYB, MT-CO1, and MT-ATP6 in LPS246 cells constitutively 
expressing TetO-FBP2 or Tet-FBP24KA, treated with vehicle or dox.  
(B) qRT-PCR analysis of MT-ND1, MT-CYB, MT-CO1, and MT-ATP6 in LPS246 cells constitutively 
expressing vector, FBP2 or FBP2G260R.  
Error bars represent SD of three experimental replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001. n.s., not significant.  
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Nuclear FBP2 Impairs Mitochondrial Biogenesis 
    To determine whether reduced transcription of OXPHOS genes in FBP2-expressing cells 
correlated with decreased mitochondrial biogenesis, we first measured mitochondrial DNA content 
by using real-time quantitative PCR. Mitochondrial to nuclear DNA ratios were dramatically 
decreased in FBP2-expressing LPS246 cells (Figure 16A), and flow cytometric analysis of cells 
stained with MitoTracker further revealed that FBP2 induction reduced mitochondrial mass (Figure 
16B). Similarly, we observed a dramatic decrease in citrate synthase activity after restoring 
expression of FBP2 in LPS246 cells (Figure 16C). Decreased mitochondrial biogenesis in FBP2-
expressing LPS246 cells was further confirmed by transmission electron microscopy, indicated by 
reduced number of mitochondria and swollen mitochondria with disorganized cristae (Figure 16D). 
Consistently, LPS246 xenograft sections exhibited reduced staining of Vdac (voltage-dependent 
anion channel) and Tomm20 (a constitutively expressed mitochondrial protein) in dox-treated 
tumors, supporting decreased mitochondrial mass caused by FBP2 expression (Figure 16E). As 
doxycyline has been reported to interfere with mammalian protein synthesis and disrupt 
mitochondrial proteostasis and function (Moullan et al., 2015), we confirmed that mtDNA content, 
MitoTracker staining, and citrate synthase activity were comparable in both vehicle and dox-treated 
LPS246 TetO-FBP24KA cells (Figure 16A-C). Collectively, these data demonstrate that nuclear 
FBP2 inhibits mitochondrial biogenesis in LPS246 cells. 
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Figure 16. Nuclear FBP2 impairs mitochondrial biogenesis. 
(A) qPCR analysis of mitochondrial (MT-ND1) versus nuclear (b-globin) DNA content in indicated 
cells (three experimental replicates).  
(B) LPS246 TetO-FBP2 cells and TetO-FBP24KA cells stained with MitoTracker Green FM probe. 
Flow cytometry plots (left) show the fluorescence intensity corresponding to mitochondrial mass. 
Histograms (right) show the quantification (three experimental replicates).  
(C) Citrate synthase activity measured in indicated cells (three experimental replicates).  
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(D) Ultrastructural analysis of mitochondria in LPS246 Teto-FBP2 cells using transmission electron 
microscopy. Scale bars: 1 µm. Quantification of the number of mitochondria per cell in the imaged 
section (vehicle treated, n = 10 cells; dox treated, n = 10 cells).  
(E) Immunohistochemical staining for expression of voltage-dependent anion channel (Vdac) and 
Tomm20 on sections from LPS246 TetO-FBP2 xenografts treated with vehicle or dox. Five fields 
per slide were quantified. Scale bars: 100 µm.  
Data are represented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not 
significant.  
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FBP2 Suppresses Mitochondrial Respiration and the TCA Cycle 
    The effects of FBP2 expression on mitochondrial OXPHOS activity were investigated by culturing 
LPS246 cells in glucose-free medium containing 5 mM galactose, which cannot be fermented, 
requiring cells to rely on mitochondrial metabolism to generate sufficient ATP for survival (Rossignol 
et al., 2004). We observed increased apoptosis in dox-treated LPS246 TetO-FBP2 cells cultured 
in galactose medium (Figure 17A-B) compared to vehicle-treated cells, indicating that mitochondrial 
OXPHOS is critically impaired upon FBP2 induction. Furthermore, oxygen consumption rates (OCR) 
and ATP production were lower in FBP2-expressing LPS246 cells compared to controls (Figure 
17C-D, I). In contrast, FBP24KA expression had no effect on OCR in LPS246 cells (Figure 17E-F). 
Loss of ATP-generating capacity stimulated glycolytic compensation in both LPS246 TetO-FBP2 
and TetO-FBP24KA cells, as indicated by extracellular acidification rate (ECAR) (Figure 17G-H). 
Interestingly, ECAR was lower in both FBP2- and FBP24KA-expressing LPS246 cells than control 
cells (Figure 17G-H), indicating inhibition of glycolysis by each protein. These results are consistent 
with our previous conclusion that FBP2 suppresses glucose uptake and lactate secretion (Figure 
9-11). In active mitochondria, a small percentage of electrons are prematurely leaked to O2 from 
complex I and/or complex III, resulting in the formation of reactive oxygen species (ROS) 
(Chatterjee et al., 2011). As expected, reduced OCRs observed in FBP2-expressing LPS246 cells 
correlated with a substantial decrease in ROS levels; whereas FBP24KA had no effect on ROS 
accumulation (Figure 17J).  
    To assess the effects of FBP2 expression on TCA cycle metabolite levels, we performed isotope 
tracing experiments by labeling vehicle- or dox-treated LPS246 TetO-FBP2 cells with [3-
13C]pyruvate. Labeled pyruvate is converted to acetyl-CoA by mitochondrial pyruvate 
dehydrogenase, which then combines with oxaloacetate to produce M1-labeled citrate. When 
acetyl-CoA is abundant, pyruvate decarboxylase can also generate M1-labeled oxaloacetate, 
which then incorporates M1-labeled acetyl-CoA to produce M2-labeled citrate (Figure 18A). We 
observed decreased M1 and M2 enrichment of three TCA intermediates (citrate, fumarate and 
malate), as well as glutamic acid and aspartic acid (Figure 18B-E) in FBP2-expressing cells. In 
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contrast, ectopic FBP24KA expression had no effect on M1 and M2 enrichment of TCA intermediates 
and products compared with control cells (Figure 18F-I), further indicating that it is nuclear FBP2 
that restrains mitochondrial function and metabolism.  
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Figure 17. FBP2 suppresses mitochondrial respiration. 
(A) LPS246 cells cultured in 5 mM glucose and 5 mM galactose medium. Apoptotic cells measured 
through Annexin V/PI staining followed by flow cytometry.  
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(B) Indicated cells were cultured in 5 mM glucose and 5 mM galactose medium. Flow cytometry 
plots of annexin V/PI staining of indicated cells.  
(C-F) Relative oxygen consumption rate normalized to protein abundance in LPS246 TetO-FBP2 
cells (C) or LPS246 TetO-FBP24KA cells (E) treated with vehicle or dox. Histogram showing basal, 
ATP-linked and maximal respiration in LPS246 TetO-FBP2 cells (D) or LPS246 TetO-FBP24KA cells 
(F) treated with vehicle or dox. Data are presented as mean ± SD of three reading cycles of n = 9 
wells pooled from three independent experiments.  
(G and H) Relative extracellular acidification rate (ECAR) normalized to protein abundance in 
LPS246 TetO-FBP2 cells (G) or LPS246 TetO-FBP24KA cells (H) treated with vehicle or dox. Data 
are presented as mean ± SD of three reading cycles of n = 9 wells pooled from three independent 
experiments. 
(I) ATP production was measured in indicated cells.  
(J) Fluorescence intensity of MitoSox analyzed by flow cytometry. Flow cytometry plots (left) show 
the fluorescence intensity. Histograms (right) display their quantification (three experimental 
replicates). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not significant.  
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Figure 18. Nuclear FBP2 inhibits the TCA cycle in LPS246 cells. 
(A) Carbon fate map showing the isotopomer distribution of indicated metabolites derived from [3-
13C]pyruvate. 13C atoms are depicted as filled circles. 13C atoms directly going through the acetyl-
CoA are colored in red, while 13C atoms going through oxaloacetate and combined with acety-CoA 
to generate citrate are colored in blue. 
(B-E) M1 isotopomer distribution of indicated TCA metabolites (A) and amino acids (B), and M2 
isotopomer distribution of indicated TCA metabolites (C) and amino acids (D) in LPS246 TetO-
FBP2 cells with vehicle or dox treatment, labelled with [3-13C]pyruvate.  
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(F-I) M1 isotopomer distribution of indicated TCA metabolites (F) and amino acids (G), and M2 
isotopomer distribution of indicated TCA metabolites (H) and amino acids (I) in LPS246 TetO-
FBP24KA cells with vehicle or dox treatment, labelled with [3-13C]pyruvate.  
Error bars represent SD of three experimental replicates except in B and C. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001. n.s., not significant.  
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FBP2 Transcriptionally Represses Mitochondrial Biogenesis  
    Mitochondrial biogenesis and function are controlled by a set of nuclearly-encoded transcription 
factors, including PPAR-γ coactivators (PGC-1a), nuclear respiratory factor 1 (NRF1), and 
mitochondrial transcription factor A (TFAM) (Scarpulla, 2012). As nuclear FBP2 regulates 
mitochondrial function, we hypothesized that FBP2 dampens mitochondrial biogenesis through 
inhibiting one or more of these nuclear regulators. Quantitative RT-PCR analyses revealed 
significant downregulation of NRF1 and TFAM expression upon FBP2 restoration (Figure 19A). 
Ectopic expression of TFAM or NRF1 reversed the suppression of target genes associated with 
OXPHOS (MT-ND1, MT-CYB, MT-CO1 and MT-ATP) (Figure 19B-C, Figure 20A-B), and partially 
restored mitochondrial mass (Figure 19D, Figure 20C). Moreover, ectopic TFAM or NRF1 
expression partially reversed cell apoptosis (Figure 19E, Figure 20D) and proliferation (Figure 19F, 
Figure 20E) in dox-treated LPS246 TetO-FBP2 cells.  
To elucidate the molecular mechanisms whereby FBP2 alters the expression of nuclear 
transcription factors associated with mitochondrial biogenesis, we examined the top differentially 
expressed pathways based on RNA-seq data and identified Myc target genes as one of the top 
downregulated gene sets (Figure 14A). Previous studies have demonstrated that c-Myc regulates 
mitochondrial biogenesis and gene expression (Lee et al., 2017; Scarpulla, 2008); for example, c-
Myc induces NRF1 target genes by binding to a canonical NRF1 binding site, leading to the 
sensitization of cells to apoptosis (Morrish et al., 2003). In addition, c-Myc potentiates mitochondrial 
biogenesis through induction of TFAM and other nuclear-encoded mitochondrial genes (Li et al., 
2005). To ascertain that FBP2 diminishes c-Myc transcriptional activity, we measured c-Myc 
luciferase-reporter intensity and found FBP2 decreased c-Myc functionality (Figure 21A). Transcript 
levels of c-Myc target genes (CCND2, eIF2A, NPM1, PSAT1) were also decreased in FBP2-
expressing cells (Figure 21B). To determine whether FBP2 represses mitochondrial biogenesis in 
a predominantly c-Myc dependent manner, we assessed the expression of mitochondrial genes 
(MT-ND1, MT-CO1 and MT-ATP6) in the presence and absence of c-Myc using RNA interference. 
Interestingly, dox-induced FBP2 expression or sic-Myc resulted in comparable repression of 
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mitochondrial gene transcription (Figure 21C-D), and combined FBP2 expression and sic-Myc 
showed no additive effects on gene expression. MitoTracker staining indicated a slight but 
perceptible decrease in mitochondrial mass in cells with combined dox and sic-Myc treatment, 
relative to cells with either treatment alone (Figure 21E). We conclude that FBP2’s inhibition of 
mitochondrial biogenesis is largely, but not entirely dependent on the c-Myc pathway.  
c-Myc has been reported to bind TFAM in the region of amplicons 1 and 2, approximately 900 
bp upstream of the transcription start site (Figure 22A), thereby stimulating TFAM expression (Li et 
al., 2005). Remarkably, chromatin immunoprecipitation (ChIP) analyses indicated that FBP2 
protein was enriched at amplicon 1, which contains a 5’-CACGTG-3’ c-Myc binding site, but not at 
amplicon 2, which contains a Myc/Max 5’-GCG-3’ half site (Figure 22B). As expected, nucleus-
excluded FBP24KA was not detected at either amplicon (Figure 22B). Importantly, ChIP-reChIP 
analyses revealed co-localization of c-Myc and FBP2 proteins at TFAM promoter amplicon 1 
(Figure 22C). We also demonstrated the association of epitope-tagged FBP2 or FBP24KA and 
endogenous c-Myc by co-immunoprecipitations in LPS246 cell lysates (Figure 22D), suggesting 
their physical interaction can occur in both the nucleus and cytosol (albeit at lower levels). Finally, 
GST pull-down assays of bacterially expressed proteins further revealed that FBP2 directly binds 
to c-Myc (Figure 22E). Collectively, these results indicate that FBP2 inhibits c-Myc transcriptional 
activation of TFAM, by direct physical association at its promoter. 
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Figure 19. Ectopic expression of TFAM partially rescued mitochondrial biogenesis. 
(A) qRT–PCR analysis of NRF1 and TFAM in vehicle treated or dox-treated LPS246 TetO-FBP2 
cells. 
(B) Immunoblot analysis for ectopic expression of vector control or TFAM in LPS246 TetO-FBP2 
cells.  
(C) qRT-PCR analysis of MT-ND1, MT-CYB, MT-CO1, and MT-ATP6 in indicated cells.  
(D) LPS246 TetO-FBP2 cells with or without TFAM expression stained with MitoTracker Green FM 
probe. Fluorescence intensity corresponding to mitochondrial mass is shown in histograms.  
(E) Indicated cells cultured in 5 mM glucose and 5 mM galactose medium, where apoptotic cells 
were measured through Annexin V/PI staining followed by flow cytometry.  
(F) Growth of indicated cells in low serum medium (1% FBS).  
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Figure 20. NRF1 partially rescues FBP2-mediated inhibition of mitochondrial biogenesis.  
(A) Immunoblot analysis for ectopic expression of vector control or NRF1 in LPS246 TetO-FBP2 
cells.  
(B) qRT-PCR analysis of MT-ND1, MT-CYB, and MT-CO1 in indicated cells.  
(C) LPS246 TetO-FBP2 cells with or without NRF1 expression were stained with MitoTracker 
Green FM probe. Fluorescence intensity corresponding to mitochondrial mass is shown in 
histogram.  
(D) Indicated cells were cultured in 5 mM glucose and 5 mM galactose medium. Apoptotic cells 
were measured through Annexin V/PI staining followed by flow cytometry.  
(E) Growth of indicated cells in low serum medium (1% FBS).  
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Figure 21. FBP2 inhibits mitochondrial biogenesis in a c-Myc dependent manner. 
(A) c-Myc reporter activity measured in LPS246 TetO-FBP2/FBP24KA cells transfected with 
Myc/Max luciferase reporter, in the presence of vehicle or dox. Transfection efficiencies were 
normalized to co-transfected pRenilla-luciferase.  
(B) qRT-PCR analysis of c-Myc target genes (CCND2, eIF2A, NPM1, PSAT1) in indicated cells. 
(C and D) qRT-PCR analysis of c-Myc (C) and MT-ND1, MT-CO1 and MT-ATP6 (D) in LPS246 
TetO-FBP2 cells under four conditions (+ Veh, siControl; + Dox, siControl; + Veh, sic-Myc; + Dox, 
sic-Myc). 
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(E) LPS246 TetO-FBP2 cells treated with four conditions stained with MitoTracker Green FM probe. 
Histogram shows the quantification of fluorescence intensity corresponding to mitochondrial mass.  
Data are represented as mean ± SD (three experimental replicates) *p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001. n.s., not significant.  
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Figure 22. FBP2 suppresses TFAM expression by co-localizing with c-Myc at the promoter 
region of TFAM. 
(A) Diagram of 2 kb upstream of exon 1 to exon 2 of human TFAM. Exons are represented by 
green boxes. The E box in amplicon 1 is illustrated. Horizontal bars labeled Neg, 1, 2 indicate the 
regions amplified for ChIP analysis.  
(B) ChIP assays evaluating FBP2 association with chromatin at a c-Myc binding site in TFAM 
promoter (amplicon 1 and 2), or to a site negative for c-Myc binding (amplicon Neg). IgG, isotype-
matched immunoglobulin G; V5, V5-tagged FBP2.  
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(C) ChIP-reChIP analysis examining the co-localization of c-Myc and FBP2 at amplicon 1 and 2 at 
TFAM promoters. 
(D) V5 tagged FBP2 or FBP24KA-expressing LPS246 cell lysates were immunoprecipitated with IgG, 
or V5 antibody and blotted for endogenous c-Myc. IP, immunoprecipitate. 
(E) GST pull-down analysis between recombinant His-FBP2 and recombinant GST or GST-tagged 
c-Myc and blotted using FBP2 antibody.  
Data are represented as standard error of the mean (three technical replicates from a 
representative experiment). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., not significant.  
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Discussion 
    Soft-tissue sarcomas (STS) are a complex set of mesenchymal malignancies, compromising 
more than 70 subtypes (Fletcher, 2014). Despite rapid advances in the molecular analysis of 
individual subtypes, the heterogeneous nature of sarcomas limits the efficacy of targeted therapies 
(Cancer Genome Atlas Research Network, 2017; Linch et al., 2014), emphasizing the need to 
identify therapeutic vulnerabilities common to multiple STS subtypes. Although a diverse spectrum 
of oncogenic mutations has been recently described for in STS (Barretina et al., 2010; Cancer 
Genome Atlas Research Network, 2017; Eisinger-Mathason et al., 2015; Frith et al., 2013; 
Nakazawa et al., 2016a), it is increasingly clear that all tumors must adapt cell metabolism to 
support growth. Whereas metabolic reprogramming in STS has long been observed (Shaw et al., 
1988), how this influences sarcoma growth is unclear. In the current study, we demonstrate that 
the gluconeogenic enzyme FBP2 is uniformly depleted in multiple sarcoma subtypes. Restoring 
FBP2 expression in sarcoma cells dramatically inhibited tumor cell growth both in vitro and in vivo 
(Figure 6-8), suggesting that FBP2 has tumor suppressive activities in sarcomas. We further 
discovered that FBP2 exhibits two distinct tumor-suppressive functions that depend on its 
subcellular localization. These results identify a specific metabolic adaptation as a common feature 
of STS and could help inform therapeutic strategies.  
Tumor cells are typified by enhanced glycolysis, as a means of generating ATP and providing 
building blocks for macromolecule biosynthesis, sometimes known as the “Warburg effect” (Vander 
Heiden and DeBerardinis, 2017; Warburg, 1956). Reprogrammed glucose metabolism is induced 
by multiple mechanisms, such as the deregulation of oncoproteins and tumor suppressors (Hay, 
2016). Previous studies uncovered frequently mutated genes in STS, including TP53, NF1 and 
PIK3CA (Barretina et al., 2010; Frith et al., 2013), further confirmed by recent large-scale analyses 
of 206 adult soft tissue sarcomas representing 6 major subtypes using multi-platform molecular 
profiling (Cancer Genome Atlas Research Network, 2017). The p53 protein is involved in regulation 
of glucose metabolism by promoting OXPHOS and dampening glycolysis (Humpton and Vousden, 
2016). Furthermore, PIK3CA mutations, among the most frequent somatic mutations found in STS 
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along with gain of function mutations in c-KIT and PDGFRa, are implicated in activation of the 
AKT/mTOR pathway (Fruman et al., 2017; Yuan and Cantley, 2008), stimulating a shift towards 
aerobic glycolysis (Lien et al., 2016). We show here that FBP2 loss also underlies increased 
glycolytic activity observed in sarcomas, as FBP2 re-expression inhibits glucose uptake and lactate 
secretion in distinct sarcoma cell lines. We also observed decreased glycolytic intermediates for 
biosynthesis in FBP2-expressing cells, such as glucose-6-phosphate, serine and glycine, 
consistent with previous speculation that FBP2 participates in the regulation of glycolysis 
(Newsholme and Crabtree, 1970). Furthermore, FBP2 restoration reduces PPP activity needed for 
ribonucleotide production and reducing equivalents in the form of NADPH.  
Increasing evidence shows that multiple essential glycolytic/gluconeogenic enzymes localize to 
the nucleus and influence gene transcriptional regulation (Boukouris et al., 2016; Huangyang and 
Simon, 2018). We suggest a model in which metabolic enzymes transduce signals from growth 
factors, nutrient and oxygen availability, and external stress to modulate gene expression. We 
reported previously that nuclear FBP1 functions as a transcriptional corepressor to inhibit HIF-1a 
and its downstream targets, including genes associated with glucose metabolism (GLUT1, LDHA, 
and PDK1), therefore decreasing glycolytic phenotypes and enhancing glutamine uptake in tumor 
cells (Li et al., 2014). FBP2 has been previously shown to reside in nuclei of myogenic progenitor 
cells, cardiomyocytes and smooth muscle cells (Gizak and Dzugaj, 2003; Gizak et al., 2005; 2006), 
although its nuclear function was unclear. We determined that FBP2 nuclear activity suppresses 
sarcoma cell growth by inhibiting mitochondrial biogenesis and OXPHOS in a catalytic activity-
independent manner, at least in part by repressing the expression of critical transcription factors 
NRF1 and TFAM. Of note, nuclear FBP2 also plays a role in suppressing glycolysis, as nucleus-
excluded FBP24KA exhibited less potent inhibition of glucose uptake and lactate secretion than wild-
type FBP2, as indicated by [1,2-13C]glucose labeling experiments (e.g. 26% decrease in glucose 
consumption by FBP2 versus 14% by FBP24KA, Figure 10B and Figure 13G). We can account for 
this based on decreased expression of c-Myc target genes in FBP2-expressing cells from RNA-
seq (Figure 4G). c-Myc regulates virtually all genes involved in glycolysis (Dang et al., 2006), 
 71 
 
including the essential glycolytic enzymes LDHA, PDK1 and ENO1, consistent with our observation 
that nuclear FBP2 also contributes to changes in glucose catabolism.  
It’s noteworthy that even though FBP1 and FBP2 have different tissue distributions, they share 
many functional similarities due to 77% sequence homology. For example, enforced expression of 
FBP1 in sarcoma cells or FBP2 in renal cancer cells suppresses tumor cell proliferation (Figure 
23A-D). In addition, we showed that c-Myc transcriptional activity can also be suppressed by FBP1 
in sarcoma cells (Figure 23E). Interestingly, in contrast to c-Myc, the effect of FBP1 and FBP2 on 
HIF signaling is tissue type-dependent. We consistently observed increased HRE luciferase activity 
upon FBP1/FBP2 expression in different sarcoma cell lines (Figure 23F-J). However, both proteins 
inhibit HIF transcriptional output in renal cancer cells. These results are in line with our previous 
findings that HIF2a is actually a tumor suppressor in soft tissue sarcoma, unlike kidney cancer 
(Nakazawa et al., 2016a) and increased HIF activity might also be involved in FBP2-mediated 
growth inhibition.  
Recent isotope tracing analysis of human ccRCC confirmed enhanced glycolysis and 
suppressed glucose oxidation by the TCA cycle in these tumors (Courtney et al., 2018), likely due 
to HIF stabilization caused by frequent von Hippel-Lindau (VHL) mutations (Nickerson et al., 2008). 
However, sarcoma cells exhibited more active mitochondrial metabolism than ccRCC, as the 
incorporation rate of 13C from [1,2-13C]glucose into TCA cycle intermediates is faster (Figure 10E-
F; see (Li et al., 2014)), suggesting that mitochondrial activity is critical for sarcoma progression. 
While earlier studies emphasized the importance of glycolysis, mitochondrial biosynthesis, 
bioenergetics, and signaling are also essential for tumorigenesis (Weinberg and Chandel, 2015). 
Intermediates from the TCA cycle, such as citrate, aspartate and glutamate, are precursors for 
macromolecule synthesis (lipid and nucleotides) to support biomass accumulation (Birsoy et al., 
2015; Faubert et al., 2017; Hosios et al., 2016; Sellers et al., 2015). In addition, the mitochondrial 
ETC produces ROS via oxidative metabolism. Elevated ROS levels activate signaling pathways to 
promote cell proliferation and tumor progression (Schieber and Chandel, 2014). By inhibiting 
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mitochondrial function, FBP2 reduces the abundance of TCA cycle intermediates, ATP, and ROS, 
therefore inhibiting cell growth.  
A key observation is that FBP2 co-localizes with the c-Myc oncogene at the TFAM promoter, 
suggesting that FBP2 acts as a nuclear c-Myc transcriptional corepressor. c-Myc affects a large 
spectrum of genes involved in mitochondrial function (Kim and Dang, 2005) and directly activates 
TFAM expression. Given the multitude of biological processes c-Myc regulates, the precise 
mechanisms whereby FBP2 specifically targets c-Myc-induced mitochondrial biogenesis remain to 
be elucidated. Presumably, additional factors are required to regulate c-Myc driven targets 
associated with mitochondrial functions. Another nuclearly-encoded transcription factor, NRF1 is 
key to mitochondrial biogenesis and also an upstream regulator of TFAM (Kelly and Scarpulla, 
2004). Decreased NRF1 expression in FBP2-expressing cells further explains reduced TFAM 
activity in this context.  
Interestingly, FBP2 has been reported to translocate from the nucleus to the cytosol during 
myoblast differentiation (Gizak et al., 2006), which corresponds to a shift from a highly glycolytic 
state to increased OXPHOS needed in fully developed muscle cells (Remels et al., 2010). We 
suggest that FBP2 is restricted to the nucleus in muscle progenitors to transcriptionally suppress 
mitochondrial biogenesis and OXPHOS, as undifferentiated cells frequently favor glycolytic 
metabolism. At the onset of differentiation, FBP2 exits the nucleus and functions as a 
gluconeogenic/glycogen producing enzyme to antagonize glycolysis in the cytosol. How FBP2 
translocation is regulated and whether subcellular shuttling of FBP2 contributes to muscle 
differentiation are unclear, and remain part of our future studies. It will also be important to evaluate 
the role of FBP2 in adipogenic differentiation, another lineage derived from mesenchymal stem 
cells.  
    In summary, our findings demonstrate a role for FBP2 in suppressing sarcoma progression and 
further establish dual tumor-suppressive functions of FBP, including promoting gluconeogenesis 
and inhibiting mitochondrial biogenesis by inhibiting c-Myc transcriptional activity (Figure 24). 
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Figure 23. Functional similarity of FBP1 and FBP2 in different tumor type.  
(A and B) Growth of RCC10 cells in low serum medium (1% FBS) (A) or low glucose medium (5 
mM glucose) (B), with or without ectopic FBP2 expression.  
(C and D) Growth of LPS246 cells in low serum medium (1% FBS) (C) or low glucose medium (5 
mM glucose) (D), with or without ectopic FBP1 expression.  
(E) c-Myc reporter activity measured in vector-, FBP1- or FBP2-expressing LPS246 cells 
transfected with Myc/Max luciferase reporter. Transfection efficiencies were normalized to co-
transfected pRenilla-luciferase.  
(F-J) HRE reporter activity measured in vector-, FBP1- or FBP2-expressing RCC10 cells (F), 
LPS224 cells (G), LPS246 cells (H), T778 cells (I), and HT1080 cells (J) transfected with Myc/Max 
luciferase reporter. Transfection efficiencies were normalized to co-transfected pRenilla-luciferase.  
n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.  
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Figure 24. Model depicting the metabolic status, transcription activity and mitochondrial 
change of sarcoma cells upon FBP2 re-expression. The cytosolic FBP2 inhibits glycolysis and 
following TCA cycle. The nuclear FBP2 restrains mitochondrial function by co-localizing with c-Myc 
at the promoter region of TFAM, a nuclearly encoded transcription factor that is crucial for 
mitochondrial biogenesis.  
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CHAPTER 4 CONCLUSIONS 
    Over the past decade, study of cellular metabolism has been rigorously revisited, especially in 
the field of cancer research, revealing new insights that significantly expand our understanding of 
cancer. However, general metabolic alterations in soft tissue sarcomas are largely understudied 
and there appear to be at least some common phenotypes among diverse sarcoma subtypes. The 
extent of soft tissue sarcoma heterogeneity has led to questions about the usefulness of targeting 
individual signaling molecules as a practical therapeutic strategy. As described in Chapter 1, 
abnormal glucose metabolism, which has long been observed in sarcoma patients, could be 
exploited as a potential therapeutic target. In order to expand our understanding of increased 
glucose catabolism in sarcoma patients, my thesis aims to investigate the impact of FBP2 loss on 
sarcoma progression by depicting its canonical enzymatic activity in gluconeogenesis and non-
canonical functions in the nucleus. I determined that FBP2 exhibits two distinct tumor-suppressive 
functions depending on its subcellular localization.  
In Chapter 3, I demonstrated that FBP2 re-expression in sarcoma cells significantly suppresses 
tumor cell growth both in vitro and in vivo, indicating that FBP2 acts as a tumor suppressor in 
sarcomas. I further revealed that FBP2 restoration significantly inhibits glycolysis, the TCA cycle 
and the pentose phosphate pathway. However, decreased glycolytic activity is not only based on 
FBP2’s catalytic activity, as ectopic expression of nuclear excluded FBP24KA exhibited less potent 
inhibition of glycolysis. These results indicate that nuclear FBP2 is also implicated in regulating 
glucose metabolism.  
    Interestingly, accumulating evidence indicates that various metabolic enzymes have surprisingly 
novel activities outside of their established metabolic roles, including regulating gene expression, 
cell cycle progression, and apoptosis (Huangyang and Simon, 2018). Many of these new functions 
are activated in response to growth factor signaling, nutrient and oxygen availability, and external 
stress. As such, multifaceted enzymes directly link metabolism to transcription, engaging diverse 
physiological and pathological processes to maintain cell homeostasis. We compared the 
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transcriptome between control and FBP2-expressing LPS246 cells, and determined that 
mitochondrial dysfunction is the primary differentially expressed functional category. We further 
confirmed that nuclear FBP2 mediates the suppression of mitochondrial function by inhibiting the 
expression of TFAM and NRF1, two crucial nuclear regulators of mitochondrial biogenesis. 
Moreover, we determined that nuclear FBP2 colocalizes with the c-Myc transcription factor at the 
TFAM promoter region and represses c-Myc-dependent TFAM activation. Collectively, these data 
add to our current understanding of FBP2’s role in sarcoma progression and provide implications 
for STS metabolic reprogramming that should guide future clinical treatment. 
Future directions 
Restoring FBP2 expression in soft tissue sarcoma. 
Previous studies have shown that FBP1 epigenetic repression is common in several cancers, 
such as hepatocellular carcinoma (HCC), and colon and non-small cell lung, and breast cancer 
(Bigl et al., 2008; Chen et al., 2011; Liu et al., 2018). Specifically, in breast cancer cells, histone 
methyltransferase G9a and DNA methyltransferase DNMT1 are recruited to the FBP1 promoter by 
Snail, a critical factor in epithelial-to-mesenchymal transitions (EMTs), resulting in increased 
H3K9me2 and DNA methylation (Dong et al., 2013). Similarly, in lung cancer cells, zinc finger E-
box-binding homeobox 1 (ZEB1) increases DNA methylation by binding to FBP1’s promoter (Zhang 
et al., 2016). In addition, pharmacological inhibition of histone demethylase LSD1 by 
tranylcypromine remarkably upregulated FBP1 expression (Pan et al., 2013). Histone deacetylation 
is also involved in downregulating FBP1, as low FBP1 levels are correlated with high levels of 
histone deacetylase 1 (HDAC1) and HDAC2 proteins, and decreased histone H3K27 acetylation 
at FBP1’s enhancer in HCC patient tissues (Yang et al., 2017). Importantly, HDAC inhibitors, such 
as sodium butyrate, SAHA and LBH589, restored FBP1 expression in a dose-dependent manner 
(Yang et al., 2017). Interestingly, ubiquitin-mediated degradation provides another layer of 
regulation of FBP1 protein abundance in HCC, in that MAGE-A3 and MAGE-C2, which are known 
to be overexpressed in HCC, form ubiquitin ligase complexes with the tripartite motif-containing 
protein 28 (TRIM28) and facilitate TRIM28-dependent degradation of FBP1 (Jin et al., 2017).  
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As discussed above, diverse inhibitors of deacetylases or methyltransferases have been 
examined in cancers exhibiting FBP1 silencing. In Chapter 3, I showed that FBP2 expression is 
uniformly downregulated in a broad spectrum of sarcoma subtypes (Figure 2-3). Analysis of TCGA 
sarcoma database indicates that FBP2 loss is not due to copy number variation, but rather through 
epigenetic silencing, such as DNA and histone hypermethylation (data not shown). However, in 
sarcoma cells, epigenetic profiling and associated transcription factors at the FBP2 promoter 
remain to be uncovered. Therefore, it will be interesting to investigate the underlying mechanisms 
of FBP2 downregulation, and test several epigenetic inhibitors or activators to restore FBP2 
expression in sarcoma cells in the future. 
Investigating the role of FBP2 in sarcoma initiation. 
In this thesis, the main question I asked is: how is FBP2 loss affects sarcoma progression? 
However, FBP2 mRNA levels are significantly decreased in tumors at early stages relative to 
normal tissues, strongly indicating that FBP2 depletion is an essential step during sarcomagenesis. 
To determine whether FBP2 loss contributes to sarcoma initiation, we will delete FBP2 in a 
genetically engineered sarcoma mouse model, and assess whether FBP2 loss accelerates tumor 
formation. Our lab utilizes a “KP” murine model, where adenovirus-expressing Cre recombinase 
(Adeno-Cre) injection into gastrocnemius muscle simultaneously drives expression of oncogeneic 
KrasG12D and deletion of Trp53 (Eisinger-Mathason et al., 2013; Kirsch et al., 2007; Mito et al., 
2009). These genetic changes occur frequently in sarcoma, and murine tumors that develop 
recapitulate human UPS morphologically, histologically, and genetically. We will use a 
CRISPR/Cas9 system to delete FBP2 in this KP model.  CRISPR-Cas9 knockin mice were 
previously generated by inserting a Cas9 transgene expression cassette into the Cre-dependent 
Rosa26 locus for genome editing and cancer modeling (Platt et al., 2014). We crossed the 
CRISPR-Cas9 knockin mice with KP mice to generate Cas9KP mice, and therefore AAV-Cre 
injection should simultaneously activate Cas9 and oncogenic Kras, and deplete p53. The use of 
Cas9 mice in conjunction with sgRNA delivery allowed us to introduce an FBP2 knockout in the 
same animal to more closely recapitulate the nature of mutation accumulation in evolving tumors. 
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By comparing tumor initiation time between Cas9KP mice injected with AAV-Cre-sgLacZ or AAV-
Cre-sgFBP2, we will be able to answer whether FBP2 loss is an essential event during early 
sarcomagenesis.  
Exploring the potential correlation between muscle differentiation and FBP2 subcellular 
localization. 
For some time, FBP2 has been considered as a key enzyme of glycogen synthesis, which is 
soluble and freely diffused in the cytoplasm. However, a previous study indicates that in dividing 
myoblasts, FBP2 is localized to both cytosol and nuclei; whereas in differentiated myofibers, FBP2 
is restricted to the cytosolic compartment (Gizak et al., 2006). In addition, my preliminary data also 
showed FBP2 translocation from nucleus to cytosol in human and mouse myoblast. Interestingly, 
the nuclear-cytosolic shuttling during muscle differentiation is consistent with my findings of FBP2’s 
specific functions in different cellular compartments described in this thesis.  A shift from a highly 
glycolytic state to relying predominantly on OXPHOS has been observed during skeletal myoblast 
differentiation (Remels et al., 2010). We conclude that FBP2 is restricted to the nucleus in muscle 
progenitors, and transcriptionally suppresses mitochondrial biogenesis and OXPHOS. At the onset 
of differentiation, FBP2 exits the nucleus and functions as a gluconeogenic/glycogen producing 
enzyme to antagonize glycolysis in the cytosol. Of note, previous studies showed that cytosolic 
FBP2 binds to mitochondria and protects mitochondria from calcium-induced mitochondrial 
swelling and ensures ATP production in cardiomyocytes (Gizak and Rakus, 2012; 2014). The 
differential acts of FBP2 on mitochondria depends on its subcellular localizations, reflecting a 
complex and exquisite control of energy usage on each differentiation stage of these cells. 
A conserved nuclear localization sequence “203KKKGK207” was identified in FBP1 and FBP2 
(Gizak et al., 2005; 2009a). Interestingly, a potential target of Casein Kinase 2, Ser 10, is located 
closely to FBP2’s NLS sequence, suggesting that nuclear transport of FBP2 might be regulated by 
phosphorylation of this amino acid residue (Gizak et al., 2005). We speculate that nutrient 
availability and growth factor signaling affect FBP2 translocation, and therefore activate its different 
functions in the cytosol and nucleus. However, the underlying mechanisms of FBP2 translocation 
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and whether subcellular shuttling of FBP2 contributes to muscle differentiation are unclear, and 
remain part of our future studies.  
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